<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005982</article-id><article-id pub-id-type="pmc">PMC11860145</article-id><article-id pub-id-type="doi">10.3390/ph18020168</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Stereoselective Synthesis and Antimicrobial Studies of <italic toggle="yes">Allo</italic>-Gibberic Acid-Based 2,4-Diaminopyrimidine Chimeras</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-7670-1097</contrib-id><name><surname>Depp</surname><given-names>Dima</given-names></name><xref rid="af1-pharmaceuticals-18-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Seb&#x00151;k</surname><given-names>No&#x000e9;mi Regina</given-names></name><xref rid="af2-pharmaceuticals-18-00168" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1651-4623</contrib-id><name><surname>Szekeres</surname><given-names>Andr&#x000e1;s</given-names></name><xref rid="af2-pharmaceuticals-18-00168" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2432-8409</contrib-id><name><surname>Szakonyi</surname><given-names>Zsolt</given-names></name><xref rid="af1-pharmaceuticals-18-00168" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00168" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Wujec</surname><given-names>Monika</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Bogucka-Kocka</surname><given-names>Anna</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Ko&#x00142;odziej</surname><given-names>Przemys&#x00142;aw</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Bogucki</surname><given-names>Jacek</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00168"><label>1</label>Institute of Pharmaceutical Chemistry, University of Szeged, E&#x000f6;tv&#x000f6;s Utca 6, H-6720 Szeged, Hungary; <email>dima.depp@hotmail.com</email></aff><aff id="af2-pharmaceuticals-18-00168"><label>2</label>Department of Microbiology, University of Szeged, K&#x000f6;z&#x000e9;p Fasor 52, H-6726 Szeged, Hungary; <email>sebok.noemi024@gmail.com</email> (N.R.S.); <email>andras.j.szekeres@gmail.com</email> (A.S.)</aff><author-notes><corresp id="c1-pharmaceuticals-18-00168"><label>*</label>Correspondence: <email>szakonyi.zsolt@szte.hu</email>; Tel.: +36-62-546809</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>168</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Gibberellins (GAs) are a family of tetracyclic <italic toggle="yes">ent</italic>-kaurenoid diterpenes found widely in several commonly used plants. Besides agricultural applications, gibberellins play an important role in the synthesis of bioactive compounds, especially those with antiproliferative and antibacterial activity. <bold>Methods</bold>: A series of gibberellic acid-based 2,4-diaminopyrimidines was designed and synthesized from commercially available gibberellic acid. The antimicrobial activity of the prepared compounds was also explored in <italic toggle="yes">B. subtilis</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli,</italic> and <italic toggle="yes">P. aeruginosa</italic> bacteria, as well as in <italic toggle="yes">C. krusei</italic> and <italic toggle="yes">C. albicans</italic> fungi. <bold>Results</bold>: The treatment of gibberellic acid with hydrochloric acid under reflux conditions resulted in aromatization followed by rearrangement to form <italic toggle="yes">allo</italic>-gibberic acid. The key intermediate azido alcohol was prepared according to the literature methods. The second key intermediate azidotriol was synthesized by the stereoselective dihydroxylation of the allylic function by the osmium (VIII)-tetroxide/NMO system. Starting from azide intermediates, click reactions were also carried out with 4-monoamino- and 2,4-diaminopyrimidines functionalized with the <italic toggle="yes">N</italic>-propargyl group. The new chimeric compounds, coupled with gibberellins thus obtained, were characterized by 1D- and 2D-NMR techniques and HRMS measurements. While the 4-monoamino-substituted derivatives exhibited only weak antibacterial activity, they demonstrated significant antifungal effectiveness against <italic toggle="yes">C. krusei</italic>. In general, 5-chloro-substituted pyrimidine derivatives displayed more consistent biological activities compared to their 5-fluoro counterparts, with the exception of one derivative, which showed acceptable activity against both <italic toggle="yes">C. krusei</italic> and <italic toggle="yes">C. albicans</italic>. The two derivatives featuring 5-chloro and 2-((4-(trifluoromethyl)phenyl)amino substituents proved to be highly effective against <italic toggle="yes">P. aeruginosa</italic>, making them promising candidates for further research. Aiming to elucidate the molecular interactions between the active compounds and their potential targets, molecular docking studies were conducted using AutoDock Vina 1.1.2. involving the most active compounds against <italic toggle="yes">P. aeruginosa.</italic>
<bold>Conclusions:</bold> The biological effects of 2-monoamino or 2,4-diamino substitution as well as the effect of chloro or fluoro substitution at position 5 of the pyrimidine ring combined with the <italic toggle="yes">allo</italic>-gibberic acid moiety were determined. Compounds with selective antibacterial activity against <italic toggle="yes">P. aeruginosa</italic> as well as selective antifungal activity against <italic toggle="yes">C. krusei</italic> and <italic toggle="yes">C. albicans</italic> fungi were identified.</p></abstract><kwd-group><kwd>GA3</kwd><kwd>diterpene</kwd><kwd><italic toggle="yes">allo</italic>-gibberic acid</kwd><kwd>2,4-diaminopyrimidine</kwd><kwd>stereoselective</kwd><kwd>antibacterial</kwd><kwd>antifungal</kwd><kwd><italic toggle="yes">P. aeruginosa</italic></kwd></kwd-group><funding-group><award-group><funding-source>Hungarian Research Foundation</funding-source><award-id>K138871</award-id></award-group><award-group><funding-source>National Research, Development and Innovation Fund</funding-source><award-id>TKP2021-EGA</award-id></award-group><funding-statement>This research was funded by financial support from the Hungarian Research Foundation (NKFI K138871). Project no. TKP2021-EGA-32 has been implemented with support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00168"><title>1. Introduction</title><p>Resistant microorganisms represent a significant global health challenge. According to a study published by the Global Research on Antimicrobial Resistance (GRAM) Project, more than 1.2 million people lost their lives in 2019 due to antibiotic-resistant bacterial infections [<xref rid="B1-pharmaceuticals-18-00168" ref-type="bibr">1</xref>]. Additionally, the Annual Epidemiological Report 2023 from the European Centre for Disease Prevention and Control highlights that, based on EARS-Net data from 2020, over 35,000 deaths occur annually in the EU/EEA as a direct result of antimicrobial-resistant infections. In 2023, the highest estimated incidence of invasive bacterial isolates reported by laboratories in the EU/EEA was attributed to <italic toggle="yes">E. coli</italic> (71.4 per 100,000 population), followed by <italic toggle="yes">S. aureus</italic> (36.9 per 100,000), <italic toggle="yes">K. pneumoniae</italic> (24.2 per 100,000), <italic toggle="yes">E. faecalis</italic> (14.1 per 100,000), <italic toggle="yes">E. faecium</italic> (10.7 per 100,000), <italic toggle="yes">P. aeruginosa</italic> (10.5 per 100,000), <italic toggle="yes">S. pneumoniae</italic> (7.2 per 100,000), and <italic toggle="yes">Acinetobacter</italic> spp. (4.6 per 100,000) [<xref rid="B2-pharmaceuticals-18-00168" ref-type="bibr">2</xref>]. Consequently, the search for new antimicrobials has become essential, as the number of non-susceptible organisms is gradually increasing, while the introduction of new antimicrobials to the market remains limited. In several cases, these were isolated from exotic marine organisms with complex structures [<xref rid="B3-pharmaceuticals-18-00168" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00168" ref-type="bibr">4</xref>]. Biologically validated products with a natural origin serve as an important resource for the development of new pharmaceuticals [<xref rid="B5-pharmaceuticals-18-00168" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00168" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00168" ref-type="bibr">7</xref>]. Their commercially available natural sources have historically provided a significant inspiration for the design and synthesis of bioactive compounds in medicinal chemistry. Gibberellins (GAs), a family of tetracyclic <italic toggle="yes">ent</italic>-kaurenoid diterpenes, are present widely in several commonly used plants, and some of them are used in agriculture as regulators to promote plant germination and growth. Gibberellic acid (GA3, <bold>I</bold>, <xref rid="pharmaceuticals-18-00168-sch001" ref-type="fig">Scheme 1</xref>) is nowadays produced commercially in large quantities by the fermentation of the fungus <italic toggle="yes">Gibberella fujikuroi</italic> and used in agriculture worldwide [<xref rid="B8-pharmaceuticals-18-00168" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-18-00168" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00168" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-18-00168" ref-type="bibr">11</xref>]. It reduces the time to flowering, and it also affects seed germination, leaf area expansion, stem elongation, and the maturation of plant sexual organs.</p><p>Besides agricultural applications, gibberellins play an important role in the synthesis of bioactive compounds, especially with antiproliferative activity [<xref rid="B12-pharmaceuticals-18-00168" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00168" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-18-00168" ref-type="bibr">14</xref>]. In 2009, Koehler discovered that gibberellic acid and 9&#x003b1;-H <italic toggle="yes">allo</italic>-gibberic acid could modulate the NF-&#x003ba;B signaling pathway [<xref rid="B15-pharmaceuticals-18-00168" ref-type="bibr">15</xref>], a transcription pathway associated with various cancer diseases [<xref rid="B16-pharmaceuticals-18-00168" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00168" ref-type="bibr">17</xref>]. In recent years, we have reported the synthesis of <italic toggle="yes">allo</italic>-gibberic acid-based aminoalcohols, aminodiols, and aminotriols and studied their antiproliferative activity [<xref rid="B18-pharmaceuticals-18-00168" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-18-00168" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00168" ref-type="bibr">20</xref>]. Similarly, the synthesis of 4-aryl-substituted triazole-coupled <italic toggle="yes">allo</italic>-gibberic acid derivatives with remarkable antiproliferative activities was reported by Wu et al. [<xref rid="B21-pharmaceuticals-18-00168" ref-type="bibr">21</xref>]. Since there are only a few articles addressing the antibacterial activity of <italic toggle="yes">allo</italic>-gibberic acid [<xref rid="B22-pharmaceuticals-18-00168" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00168" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-18-00168" ref-type="bibr">24</xref>], this encouraged us to undertake investigation in this area.</p><p>2,4-Diaminopyrimidine derivatives possess biological and pharmaceutical importance as well as antimicrobial [<xref rid="B25-pharmaceuticals-18-00168" ref-type="bibr">25</xref>], antiprotozoal [<xref rid="B26-pharmaceuticals-18-00168" ref-type="bibr">26</xref>], and anticancer therapy uses [<xref rid="B27-pharmaceuticals-18-00168" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00168" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-18-00168" ref-type="bibr">29</xref>]. Therefore, it seemed interesting to combine the <italic toggle="yes">allo</italic>-gibberic acid-based moiety with a mono- or diaminopyrimidine unit to obtain a promising chimeric structure with antimicrobial activity.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00168"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00168"><title>2.1. Synthesis of Allo-Gibberic Acid-Based Azides</title><p><italic toggle="yes">allo</italic>-Gibberic acid <bold>1</bold> was obtained starting from commercially available gibberellic acid (<bold>I</bold>) through HCl-mediated hydrolysis, which involves lactone opening, decarboxylation, and the aromatization of ring A [<xref rid="B14-pharmaceuticals-18-00168" ref-type="bibr">14</xref>,<xref rid="B19-pharmaceuticals-18-00168" ref-type="bibr">19</xref>]. Afterwards, key intermediate azide <bold>4</bold> was prepared according to the literature, as shown in <xref rid="pharmaceuticals-18-00168-sch001" ref-type="fig">Scheme 1</xref>, in a four-step synthesis via esterification, followed by LiAlH<sub>4</sub>-mediated reduction, tosylation of the primary alcohol and, finally, tosyl&#x02013;azide exchange [<xref rid="B22-pharmaceuticals-18-00168" ref-type="bibr">22</xref>]. Moreover, by the oxidation of the double bond using catalytic amounts of OsO<sub>4</sub> and NMO, we were able to synthesize another key intermediate, triol-azide <bold>5</bold>, under mild conditions [<xref rid="B30-pharmaceuticals-18-00168" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot2-pharmaceuticals-18-00168"><title>2.2. Synthesis of 2,4-Diaminopyrimidine-Derived Alkynes</title><p>Nitrogen-containing heterocycles hold a unique and significant position as a valuable source of therapeutic agents in medicinal chemistry [<xref rid="B25-pharmaceuticals-18-00168" ref-type="bibr">25</xref>,<xref rid="B28-pharmaceuticals-18-00168" ref-type="bibr">28</xref>,<xref rid="B31-pharmaceuticals-18-00168" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00168" ref-type="bibr">32</xref>]. Among them, 2,4-diaminopyrimidines are particularly important in cancer chemotherapy and the development of new antitrypanosomal, antimalarial, and antibacterial drugs [<xref rid="B26-pharmaceuticals-18-00168" ref-type="bibr">26</xref>,<xref rid="B33-pharmaceuticals-18-00168" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-18-00168" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00168" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-18-00168" ref-type="bibr">36</xref>]. Compounds <bold>8</bold>&#x02013;<bold>13</bold> were synthesized according to our recently published article starting from halogen-substituted pyrimidines and propargylamine in two steps [<xref rid="B20-pharmaceuticals-18-00168" ref-type="bibr">20</xref>]. Furthermore, we were able to synthesize new 5-fluoro- and 5-chloro-substituted 2,4-diaminopyrimidines with 4-(methoxycarbonyl)phenyl and 1-(4-morpholinophenyl) moieties, as shown in <xref rid="pharmaceuticals-18-00168-sch002" ref-type="fig">Scheme 2</xref>. The aim of these reactions was to couple the products with the diterpene skeleton. Compounds <bold>14</bold> and <bold>15</bold> have low solubility, and they precipitated in ethanol as the reaction mixture started to cool down.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00168"><title>2.3. Coupling the Diterpene Skeleton with Monoamino- and Diaminopyrimidines via Click Reaction</title><p>The CuAAC reaction (copper-catalyzed azide&#x02013;alkyne cycloaddition) is a widely used click chemistry approach for the synthesis of 1,2,3-triazoles with high efficiency and regioselectivity. Its simplicity, versatility, and compatibility with various functional groups make it invaluable in medicinal chemistry [<xref rid="B37-pharmaceuticals-18-00168" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00168" ref-type="bibr">38</xref>]. In order to prepare monoamino- and diaminopyrimidines derived from <italic toggle="yes">allo</italic>-gibberic acid, both azides <bold>4</bold> and <bold>5</bold> were subjected to a CuAAC reaction with the previously prepared alkynes, as shown in <xref rid="pharmaceuticals-18-00168-sch003" ref-type="fig">Scheme 3</xref>. Reactions were carried out under mild conditions at 45 &#x000b0;C with catalytic amounts of Cu(OAc)<sub>2</sub>.H<sub>2</sub>O and sodium ascorbate. The solubility of the corresponding alkyne played a crucial role in determining the type and amount of solvent required for the reaction. As for monoaminopyrimidines and 2,4-diaminopyrimidines with 4-(trifluoromethyl)phenyl, 1-methyl-1<italic toggle="yes">H</italic>-pyrazol-4-yl, and 1-(4-morpholino)phenyl substituents, a mixture of <italic toggle="yes">tert</italic>-BuOH and water (2:1) was used. In contrast, for compounds <bold>23</bold>, <bold>24</bold>, <bold>32</bold>, and <bold>33</bold>, involving the use of 4-(methoxycarbonyl)phenyl alkynes, a mixture of <italic toggle="yes">i</italic>-PrOH and water (2:1) or THF and water (2:1) was employed due to the insolubility of these alkynes in the <italic toggle="yes">tert</italic>-BuOH/water mixture. Moreover, the choice of solvent mixture influenced the solubility of the products during the reactions. In fact, compound <bold>32</bold> precipitated in the reaction mixture, whereas the alkyne precipitated when preparing compound <bold>23</bold>. Compounds <bold>30</bold> and <bold>31</bold> exhibited higher polarity than initially indicated by TLC analysis, necessitating the use of a more polar solvent system during column chromatography for effective separation.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00168"><title>2.4. Determination of the Relative Configuration of Azide <bold>5</bold></title><p>A new chiral center was generated by the dihydroxylation of the double bond, yielding azide <bold>5</bold>. The relative configuration of the obtained new stereocenter at position 8 was established using 2D-NMR experiments (<xref rid="pharmaceuticals-18-00168-f001" ref-type="fig">Figure 1</xref>).</p><p>Despite the complexity caused by overlapping peaks in the aliphatic range in <sup>1</sup>H NMR, clear NOE signals were observed between the CH<sub>2</sub> proton of the primary alcoholic function [3.83 ppm (dd)] and the H<sub>a</sub> proton at position 9 and similarly with CH<sub>2</sub> at positions 5 and 6. Moreover, clear NOE signals were observed between OH at position 8 and H<sub>b</sub> proton at position 9 as well as with CH<sub>2</sub> at position 11. The HO group at position 8 was determined by HMBC measurements.</p></sec><sec id="sec2dot5-pharmaceuticals-18-00168"><title>2.5. In Vitro Studies of Antimicrobial Effects of 4-Amino- and 2,4-Diaminopyrimidine Derivatives and Their Structure&#x02013;Activity Relationship (SAR)</title><p>Since several diterpenes with an allylic alcohol function as well as several 2,4-diaminopyrimidines exerted antimicrobial activities against various bacterial and fungal strains, the antimicrobial activities of the prepared mono- and trihydroxy-2,4-diaminopyrimidine analogues were tested against two yeasts as well as two Gram-positive and two Gram-negative bacteria (<xref rid="pharmaceuticals-18-00168-t001" ref-type="table">Table 1</xref>) [<xref rid="B39-pharmaceuticals-18-00168" ref-type="bibr">39</xref>]. Interestingly, key intermediate azide <bold>4</bold> with an allylic alcohol function showed more potential antimicrobial activity against both Gram-positive and Gram-negative bacteria and similarly against yeasts. It is also evident from the results presented in <xref rid="pharmaceuticals-18-00168-t001" ref-type="table">Table 1</xref> that 4-monoamino-substituted derivatives (<bold>17</bold>, <bold>18</bold>, <bold>26</bold>, and <bold>27</bold>) have only weak antibacterial activity. In contrast, these compounds possess remarkable antifungal activity against <italic toggle="yes">Candida krusei</italic>, especially compound <bold>27</bold>, which exhibits better activity compared to the reference compound <italic toggle="yes">nystatine</italic> at a concentration of 5 &#x003bc;g/mL. Generally, 5-chloro-substituted pyrimidine derivatives have more reliable biological activities compared with 5-fluoro derivatives, with the only exception of 2-(pyrazol-4-yl)amino derivative <bold>21</bold>, which possesses acceptable activity against both <italic toggle="yes">C. krusei</italic> and <italic toggle="yes">C. albicans</italic>. Derivative <bold>29</bold>, the best diaminopyrimidine with 5-chloro and 2-((4-(trifluoromethyl)phenyl)amino substituents, proved to be excellent against both <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">C. krusei</italic>, and it would be an excellent lead molecule for further investigation. Similarly, compound <bold>20</bold> [monohydroxy, with 5-chloro and 2-((4-(trifluoromethyl)phenyl substitution] shows a selective antibacterial effect against <italic toggle="yes">P. aeruginosa</italic>, while compound <bold>28</bold> was effective and selective against fungus.</p></sec><sec id="sec2dot6-pharmaceuticals-18-00168"><title>2.6. Molecular Docking</title><p>Aiming to elucidate the molecular interactions between the active compounds and their potential targets, molecular docking studies were conducted using AutoDock Vina [<xref rid="B40-pharmaceuticals-18-00168" ref-type="bibr">40</xref>]. Two compounds, <bold>20</bold> and <bold>29</bold>, which demonstrated the highest activity against <italic toggle="yes">P. aeruginosa</italic> were selected for docking.</p><p>Compounds that strongly inhibit bacterial growth are likely to disrupt fundamental processes such as DNA replication. DNA gyrase is a well-recognized target for several antibiotics, including fluoroquinolones. While fluoroquinolones act by inhibiting the GyrA subunit of the enzyme, novobiocin uniquely targets the GyrB subunit. Targeting the GyrB subunit is particularly significant because it contains the ATP-binding site, which is essential for enzymatic activity. Additionally, the conserved nature of the ATP-binding site minimizes the likelihood of spontaneous resistance to ATP-competitive inhibitors [<xref rid="B41-pharmaceuticals-18-00168" ref-type="bibr">41</xref>]. Similarly, nitrogen-containing heterocycles have the ability to mimic the structure of ATP, enabling them to effectively compete for the ATP-binding site [<xref rid="B42-pharmaceuticals-18-00168" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00168" ref-type="bibr">43</xref>]. Furthermore, our previous research suggested that allo-gibberic acid derivatives containing nitrogen heterocycles exhibit affinity for the ATP-binding sites of certain kinase enzymes [<xref rid="B20-pharmaceuticals-18-00168" ref-type="bibr">20</xref>]. As such, selecting DNA gyrase B as a docking target aligns with the compound&#x02019;s observed ability to completely inhibit <italic toggle="yes">P. aeruginosa</italic> growth. Moreover, the essential role of DNA gyrase B, its validated druggability, and the availability of high-resolution crystal structures make it an ideal target. These factors, combined with the compound&#x02019;s potential ATP-binding site affinity, enable precise docking studies to be conducted.</p><p>The DNA gyrase B structure of <italic toggle="yes">P. aeruginosa</italic> involves two amino acids, Arg78 and Arg138, which are crucial for its enzymatic activity. Additionally, it contains a hydrophobic groove formed by Ile80, Pro81, and Ile96. Moreover, a solvent-exposed area opposite two conserved amino acids, Asn48 and Asp51, may further contribute to improving the binding affinity [<xref rid="B44-pharmaceuticals-18-00168" ref-type="bibr">44</xref>]. In <xref rid="pharmaceuticals-18-00168-f002" ref-type="fig">Figure 2</xref>A, a 3D illustration shows the interactions between a known co-crystalized pyrido [2,3-<italic toggle="yes">b</italic>]indole-type inhibitor and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase B. The co-crystalized ligand has reliable interactions with key residues, as shown in <xref rid="pharmaceuticals-18-00168-f002" ref-type="fig">Figure 2</xref>B, such as Arg78, Ile80, Pro81, and Ile96, as well as Asn48. The redocking of the co-crystalized ligand with the protein for the validation of the docking protocol yielded similar poses and interactions with binding energies below &#x02013;7.0 kcal/mol and RMSD below 3 &#x000c5; (detailed information can be found in the <xref rid="app1-pharmaceuticals-18-00168" ref-type="app">Supplementary Materials</xref>).</p><p>The docking results indicate that compound <bold>20</bold> exhibits strong affinity with binding energies ranging from &#x02013;8.9 to &#x02013;8.2 kcal/mol. As suggested by the software and shown in <xref rid="pharmaceuticals-18-00168-f003" ref-type="fig">Figure 3</xref>A, compound <bold>20</bold> may form two conventional hydrogen bonds: one between a trifluoromethyl fluorine atom and Asn48 and another between the amino group and Asp51. Moreover, van der Waals interactions with Arg78 can be observed. The diterpene portion of compound <bold>20</bold> can also interact with Ile96 within the hydrophobic pocket. Similarly, compound <bold>29</bold> demonstrated high affinity, with binding energies ranging from &#x02013;9.0 to &#x02013;8.1 kcal/mol. In addition to the interactions mentioned previously, compound <bold>29</bold> may be able to form cation&#x02013;&#x003c0; and anion&#x02013;&#x003c0; stacking interactions between the pyrimidine ring and Arg78 and Glu52, as visualized in <xref rid="pharmaceuticals-18-00168-f003" ref-type="fig">Figure 3</xref>B, which might increase the affinity. All of these interactions may contribute to the binding affinity of compounds <bold>20</bold> and <bold>29</bold> with the protein, stabilizing the complex by enhancing the associations between the ligand and the receptor. On the other hand, it is worth mentioning that despite sharing the same structure with compounds <bold>20</bold> and <bold>29</bold>, with the exception of a fluorine atom replacing chlorine, compounds <bold>19</bold> and <bold>28</bold> exhibited almost no antibacterial activity against <italic toggle="yes">P. aeruginosa</italic> compared to <bold>20</bold> and <bold>29</bold>. This finding is consistent with previous results, which suggest that chlorine atom substitutions play a key role in modulating the antibacterial profile [<xref rid="B45-pharmaceuticals-18-00168" ref-type="bibr">45</xref>]. For better illustration, all 2D diagrams of the interactions of compounds with the proteins can be found in the <xref rid="app1-pharmaceuticals-18-00168" ref-type="app">Supplementary Materials</xref>.</p><p>To gain deeper insights into the structure&#x02013;activity relationship, the docking of a non-active compound was performed to compare its binding interactions with those of active compounds. Compound <bold>30</bold> was selected for this analysis. The results revealed binding affinities ranging from &#x02013;7.4 to &#x02013;6.8 kcal/mol, which are noticeably lower than the scores observed for active compounds. Although the compound was able to form four hydrogen bonds with Tyr57, Ser59, Asn76, and His139, an unfavorable interaction occurred between the 1-methyl-1H-pyrazol-4-yl group and Arg138. Moreover, the results indicated that all poses with low binding energies (below &#x02013;7.0 kcal/mol) were located outside the original ligand&#x02019;s binding site. In contrast, all poses of the active compounds were confined to the same binding site. <xref rid="pharmaceuticals-18-00168-f004" ref-type="fig">Figure 4</xref> illustrates a comparison of the binding locations of the original ligand, compound <bold>20</bold>, compound <bold>29</bold>, and compound <bold>30</bold>. Detailed 3D representations of all poses suggested by the program are provided in the <xref rid="app1-pharmaceuticals-18-00168" ref-type="app">Supplementary Materials</xref>.</p></sec></sec><sec id="sec3-pharmaceuticals-18-00168"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00168"><title>3.1. General Methods</title><p>Commercially available reagents were used as obtained from suppliers (Novochem Co., Ltd., 1089 Budapest, Hungary, Orczy &#x000fa;t 6.; Merck Ltd., Budapest, Hungary; and VWR International Ltd., Debrecen, Hungary), while solvents were dried according to standard procedures. Chromatographic separations and monitoring of reactions were carried out on Merck Kieselgel 60 (Merck Ltd., Budapest, Hungary). Optical rotations were measured in MeOH at 20 &#x000b0;C with a PerkinElmer 341 polarimeter (PerkinElmer Inc., Shelton, CT, USA). Melting points were determined with a Kofler apparatus (Nagema, Dresden, Germany). HRMS flow injection analysis was performed with a Thermo Scientific Q Exactive Plus hybrid quadrupole-Orbitrap (Thermo Fisher Scientific, Waltham, MA, USA) mass spectrometer coupled to a Waters Acquity I-Class UPLC&#x02122; (Waters, Manchester, UK). <sup>1</sup>H-, <sup>13</sup>C <italic toggle="yes">J</italic>-MOD-, and <sup>19</sup>F-NMR spectra were recorded on a Bruker Avance DRX 500 spectrometer (Bruker Biospin, Karlsruhe, Baden-W&#x000fc;rttemberg, Germany) [500 MHz (<sup>1</sup>H), 125 MHz (<sup>13</sup>C <italic toggle="yes">J</italic>-MOD), and 470 MHz (<sup>19</sup>F) &#x003b4; = 0 (TMS)]. Chemical shifts are expressed in ppm (&#x003b4;) relative to TMS as an internal reference. <italic toggle="yes">J</italic> values are given in Hz. All <sup>1</sup>H-, <sup>13</sup>C, <italic toggle="yes">J</italic>-MOD-, <sup>19</sup>F-NMR, COSY, NOESY, 2D-HMBC, and 2D-HMQC spectra are available in the <xref rid="app1-pharmaceuticals-18-00168" ref-type="app">Supporting Information file</xref>.</p></sec><sec id="sec3dot2-pharmaceuticals-18-00168"><title>3.2. Starting Materials</title><p>Natural gibberellin (GA3, <bold>I</bold>) was obtained from AK Scientific Inc., Union City, CA, USA. The preparation of <italic toggle="yes">allo</italic>-gibberic acid <bold>1</bold>, intermediates <bold>2</bold>&#x02013;<bold>4</bold>, and azide <bold>5</bold> was accomplished according to the literature methods starting from GA3 with spectroscopic data identical to those reported therein. Compounds <bold>8</bold> and <bold>9</bold> were prepared according to procedures reported in the literature [<xref rid="B20-pharmaceuticals-18-00168" ref-type="bibr">20</xref>,<xref rid="B46-pharmaceuticals-18-00168" ref-type="bibr">46</xref>].</p></sec><sec id="sec3dot3-pharmaceuticals-18-00168"><title>3.3. Synthesis of New Compounds</title><sec id="sec3dot3dot1-pharmaceuticals-18-00168"><title>3.3.1. (7S,8S,9aR,10R)-10-(Azidomethyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7H-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>5</bold>)</title><p>To a solution of <bold>4</bold> (0.91 g, 3.08 mmol) in acetone (15 mL), an aqueous solution of NMO (1.8 mL, 50% aqueous solution) and a solution of OsO<sub>4</sub> in <italic toggle="yes">tert</italic>-BuOH (1.08 mL, 2% solution) were added in one portion. The reaction mixture was stirred at room temperature for 24 h and then quenched by the addition of a saturated aqueous solution of Na<sub>2</sub>SO<sub>3</sub> (25 mL) and extracted with EtOAc (3 &#x000d7; 50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude product was purified by chromatography on silica gel by using EtOAc. Yield: 0.99 g, 98%; white crystals; m.p.: 161&#x02013;163 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;7.933 (<italic toggle="yes">c</italic> 0.3 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 1.23 (d, <italic toggle="yes">J</italic> = 14.8 Hz, 1H), 1.59&#x02013;1.50 (m, 3H), 1.91 (dd, <italic toggle="yes">J</italic> = 6.2, 13.5 Hz, 1H), 2.01 (dt, <italic toggle="yes">J</italic> = 6.0, 13.1 Hz, 1H), 2.07 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 2.32 (ddd, <italic toggle="yes">J</italic> = 6.3, 6.3, 13.1 Hz, 1H), 2.37 (s, 3H), 2.57 (s, 1H), 2.76&#x02013;2.69 (m, 2H), 3.25 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 3.28 (s, 1H), 3.59 (dd, <italic toggle="yes">J</italic> = 6.3, 11.3 Hz, 1H), 3.72 (dd, <italic toggle="yes">J</italic> = 7.3, 12.8 Hz, 1H), 3.83 (dd, <italic toggle="yes">J</italic> = 5.0, 11.4 Hz, 1H), 4.10 (dd, <italic toggle="yes">J</italic> = 6.0, 12.8 Hz, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 6.95 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.08 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl3) &#x003b4; (ppm): 20.6, 22.2, 33.5, 35.3, 45.8, 48.2, 50.9, 51.4, 53.7, 64.8, 78.0, 80.6, 120.1, 127.0, 129.73, 134.0, 140.6, 144.7. HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>36</sub>H<sub>47</sub>N<sub>6</sub>O<sub>6</sub> [2M + H]<sup>+</sup>: 659.3557. Found: 659.3552.</p></sec><sec id="sec3dot3dot2-pharmaceuticals-18-00168"><title>3.3.2. General Procedure for Preparing the <italic toggle="yes">N</italic>-Propargyl-Substituted Diaminopyrimidine Derivatives</title><p>In total, 1.0 mmol of <bold>8</bold> or <bold>9</bold> (obtained according to the literature method [<xref rid="B20-pharmaceuticals-18-00168" ref-type="bibr">20</xref>]) was dissolved in dry EtOH (8 mL), and the appropriate amine (1 eq.) was added to the solution. The reaction mixture was irradiated in a microwave reactor (200 W, 100 &#x000b0;C, 17 bar) for 2 h. After the completion of the reaction and cooling, the crude product was filtered off (<bold>14</bold> and <bold>15</bold>) or the mixture was evaporated, and the crude product was purified by column chromatography on silica gel (<bold>16</bold>).</p><sec><title>Methyl 4-((5-Fluoro-4-(prop-2-yn-1-ylamino)pyrimidin-2-yl)amino)benzoate (<bold>14</bold>)</title><p>The reaction was accomplished starting from <bold>8</bold> (0.4 g, 1.0 mmol) and methyl 4-aminobenzoate (0.165 g, 1 mmol). The product precipitating in EtOH was obtained by filtration. Yield: 0.18 g, 28%; white crystals; m.p.: 212&#x02013;214 &#x000b0;C; <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 3.14 (s, 1H), 3.80 (s, 3H), 4.17 (dd, <italic toggle="yes">J</italic> = 1.9, 5.6 Hz, 2H), 7.83 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 2H), 7.92 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 2H), 8.01&#x02013;7.95 (m, 2H), 9.62 (s, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 29.8, 52.1, 73.2, 81.8, 117.6 (2C), 121.5, 130.5 (2C), 139.7 (d, <italic toggle="yes">J</italic> = 18.7 Hz), 141.8 (d, <italic toggle="yes">J</italic> = 246.5 Hz), 146.2, 152.4 (d, <italic toggle="yes">J</italic> = 12.5 Hz), 155.6 (d, <italic toggle="yes">J</italic> = 2.9 Hz), 166.6; <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): &#x02212;167.8; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>15</sub>H<sub>14</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 301.1101. Found: 301.1091.</p></sec><sec><title>Methyl 4-((5-Chloro-4-(prop-2-yn-1-ylamino)pyrimidin-2-yl)amino)benzoate (<bold>15</bold>)</title><p>The reaction was accomplished starting from <bold>9</bold> (0.202 g, 1.0 mmol) and methyl 4-aminobenzoate (0.165 g, 1 mmol). The product precipitating in EtOH was filtrated off as pure product. Yield: 0.257 g, 81%; white crystals; m.p.: 228&#x02013;231 &#x000b0;C; <sup>1</sup>H NMR (500 MHz, DMSO) &#x003b4; (ppm): 3.12 (s, 1H), 3.81 (s, 3H), 4.17 (dd, <italic toggle="yes">J</italic> = 1.7, 5.6 Hz, 2H), 7.72 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 7.85 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.94 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 8.07 (s, 1H), 9.75 (s, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 30.4, 52.1, 72.9, 81.9, 105.2, 118.1 (2C), 121.9, 130.4 (2C), 145.8, 153.9, 157.6, 157.9, 166.5; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>15</sub>H<sub>14</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 317.0805. Found: 317.0794.</p></sec><sec><title>5-Fluoro-N<sup>2</sup>-(4-Morpholinophenyl)-N<sup>4</sup>-(prop-2-yn-1-yl)pyrimidine-2,4-diamine (<bold>16</bold>)</title><p>The reaction was accomplished starting from <bold>8</bold> (0.40 g, 1.0 mmol) and 4-morpholino aniline (0.178 g, 1.0 mmol). The product was purified by column chromatography on silica gel with DCM/MeOH (39:1). Yield: 0.37 g, 52%; white crystals; m.p.: 161&#x02013;164 &#x000b0;C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 2.28 (s, 1H), 3.11 (dd, <italic toggle="yes">J</italic> = 4.6, 4.6 Hz, 4H), 3.86 (dd, <italic toggle="yes">J</italic> = 4.6, 4.6 Hz, 4H), 4.26 (dd, <italic toggle="yes">J</italic> = 2.2, 5.4 Hz, 2H), 5.09 (s, 1H), 6.80 (s, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H), 7.46 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H), 7.81 (d, <italic toggle="yes">J</italic> = 2.7 Hz, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 30.2, 50.2 (2C), 67.0 (2C), 71.6, 79.8, 116.6 (2C), 120.7 (2C), 133.0, 139.6 (d, <italic toggle="yes">J</italic> = 19.4 Hz), 141,3 (d, <italic toggle="yes">J</italic> = 244.5 Hz), 146.9, 151.7 (d, <italic toggle="yes">J</italic> = 12.0 Hz), 156.1 (d, <italic toggle="yes">J</italic> = 2.8 Hz); <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): &#x02212;169.9; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>17</sub>H<sub>19</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 328.1574. Found: 328.1563.</p></sec></sec><sec id="sec3dot3dot3-pharmaceuticals-18-00168"><title>3.3.3. General Procedure for Preparation of 1,2,3-Triazols by Click Reaction</title><p>To a solution of azide <bold>4</bold> or <bold>5</bold> (0.304 mmol) in a mixture of <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1, 12 mL), THF/H<sub>2</sub>O (2:1, 12 mL), or <italic toggle="yes">i</italic>-PrOH/H<sub>2</sub>O (2:1, 12 mL), Cu(OAc)<sub>2</sub>&#x000b7;H<sub>2</sub>O (0.1 eq.), sodium ascorbate (0.1 eq.), and the appropriate acetylene derivative <bold>17</bold>&#x02013;<bold>34</bold> (0.334 mmol, 1.1 eq.) were added. The mixture was stirred for 48 h at 45 &#x000b0;C. In the case of crystalline product separation, the crude product was obtained by filtration. In other cases, the organic solvent was evaporated, and the residue was dissolved in water (10 mL) and then extracted with DCM or CHCl<sub>3</sub> (3 &#x000d7; 50 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated at low pressure, and the crude product was purified by column chromatography on silica gel.</p><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((2-Chloro-5-fluoropyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>17</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>8</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1), and the product was purified by column chromatography on silica gel with DCM/MeOH (19:1). Yield: 0.061 g, 42%; white crystals; m.p.: 104&#x02013;107 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;87.1 (<italic toggle="yes">c</italic> 0.28 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.39 (dd, <italic toggle="yes">J</italic> = 1.9, 10.2 Hz, 1H), 1.40 (dd, <italic toggle="yes">J</italic> = 1.9, 10.2 Hz, 1H), 1.51 (dq, <italic toggle="yes">J</italic> = 5.4, 12.8 Hz, 1H), 1.65 (s, 1H), 1.82 (dt, <italic toggle="yes">J</italic> = 5.2, 12.2 Hz, 1H), 1.93 (dd, <italic toggle="yes">J</italic> = 1.6, 17.0 Hz, 1H), 2.19 (ddd, <italic toggle="yes">J</italic> = 5.9, 5.9, 12.5 Hz, 1H), 2.38 (s, 3H), 2.61 (d, <italic toggle="yes">J</italic> = 17.1 Hz, 1H), 2.68 (dd, <italic toggle="yes">J</italic> = 5.0, 12.4 Hz, 1H), 3.84 (dd, <italic toggle="yes">J</italic> = 4.9, 11.5 Hz, 1H), 4.82&#x02013;4.70 (4H, m), 4.93 (s, 1H), 5.32 (dd, <italic toggle="yes">J</italic> = 5.1, 14.0 Hz, 1H), 6.49 (s, 1H), 6.95 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 6.97 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.12 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.77 (s, 1H), 7.89 (d, <italic toggle="yes">J</italic> = 2.6 Hz, 1H); <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.4, 21.9, 30.7, 35.9, 38.8, 47.8, 49.3, 49.6, 51.6, 53.2, 79.6, 104.1, 120.5, 123.1, 127.4, 129.9, 133.3, 139.0, 140.0 (d, <italic toggle="yes">J</italic> = 19.6 Hz), 144.2, 144.4, 145.1, 146.5, 153.3 (d, <italic toggle="yes">J</italic> = 12.7 Hz), 153.6; <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;158.8; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>25</sub>H<sub>27</sub>ClFN<sub>6</sub>O [M + H]<sup>+</sup>: 481.1919. Found: 481.1905.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((2,5-Dichloropyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>18</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>9</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Purification with column chromatography on silica gel with DCM/MeOH gave compound <bold>18</bold>. Yield: 0.050 g, 33%; white crystals; m.p.: 111&#x02013;114 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;72.87 (<italic toggle="yes">c</italic> 0.26 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.42 (dd, <italic toggle="yes">J</italic> = 2.0, 10.1 Hz, 1H), 1.43 (dd, <italic toggle="yes">J</italic> = 1.9, 10.3 Hz, 1H), 1.51 (dq, <italic toggle="yes">J</italic> = 5.3, 12.8 Hz, 1H), 1.64 (d, <italic toggle="yes">J</italic> = 12.2 Hz, 1H), 1.83 (dt, <italic toggle="yes">J</italic> = 5.2, 12.3 Hz, 1H), 1.93 (d, <italic toggle="yes">J</italic> = 17.1 Hz, 1H), 2.19 (ddd, <italic toggle="yes">J</italic> = 5.8, 5.8, 12.5 Hz, 1H), 2.38 (s, 3H), 2.58 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.68 (dd, <italic toggle="yes">J</italic> = 4.9, 12.5 Hz, 1H), 3.86 (dd, <italic toggle="yes">J</italic> = 5.0, 11.3 Hz, 1H), 4.84&#x02013;4.69 (4H, m), 4.93 (s, 1H), 5.31 (dd, <italic toggle="yes">J</italic> = 5.1, 14.1 Hz, 1H), 6.49 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 6.95 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 6.97 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.12 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.76 (s, 1H), 8.05 (s, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.3, 21.9, 30.8, 36.4, 38.8, 47.9, 49.3, 49.5, 51.5, 53.3, 79.6, 104.1, 113.7, 120.5, 123.1, 127.3, 129.9, 133.3, 139.1, 144.1, 145.1, 153.7, 153.9, 158.1, 158.5; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>25</sub>H<sub>27</sub>C<sub>l2</sub>N<sub>6</sub>O [M + H]<sup>+</sup>: 497.1623. Found: 497.1616.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((4-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>19</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>10</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Purification was performed by column chromatography on silica gel with DCM/MeOH (39:1). Yield: 0.055 g, 30%; pink crystals; m.p.: 123&#x02013;125 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;74.4 (<italic toggle="yes">c</italic> 0.33 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.53 (dd, <italic toggle="yes">J</italic> = 2.0, 10.3 Hz, 1H), 1.43 (dd, <italic toggle="yes">J</italic> = 1.9, 10.2 Hz, 1H), 1.55&#x02013;1.46 (1H, m), 1.73&#x02013;1.59 (1H, m), 1.86&#x02013;1.78 (1H, m), 1.91 (d, <italic toggle="yes">J</italic> = 17.3 Hz, 1H), 2.22&#x02013;2.14 (1H, m), 2.32 (s, 3H), 2.56 (d, <italic toggle="yes">J</italic> = 17.1 Hz, 1H), 2.64 (dd, <italic toggle="yes">J</italic> = 4.9, 12.3 Hz, 1H), 3.77 (dd, <italic toggle="yes">J</italic> = 5.1, 11.0 Hz, 1H), 4.67 (dd, <italic toggle="yes">J</italic> = 11.2, 14.0 Hz, 1H), 4.87&#x02013;4.75 (3H, m), 4.94 (s, 1H), 5.25 (dd, <italic toggle="yes">J</italic> = 5.1, 14.1 Hz, 1H), 5.84 (s, 1H), 6.93 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 6.95 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.11 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.21 (s, 1H), 7.54 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), 7.55 (s, 2H), 7.72 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.84 (s, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.2, 21.9, 30.8, 36.2, 38.9, 47.9, 49.2, 49.4, 51.5, 53.3, 79.7, 104.0, 117.9 (2C), 120.4, 122.0, 123.5, 126.1 (q, <italic toggle="yes">J</italic> = 3.7 Hz, 2C), 127.3, 129.9, 133.2, 139.0, 139.1 (d, <italic toggle="yes">J</italic> = 20.3 Hz), 141.8 (d, <italic toggle="yes">J</italic> = 246.9 Hz), 143.2, 145.0, 145.1 (2C), 152.3 (d, <italic toggle="yes">J</italic> = 12 Hz), 153.7, 155.1 (d, <italic toggle="yes">J</italic> = 3.6 Hz); <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;166.8, &#x02212;61.6; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>32</sub>H<sub>32</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup>: 606.2604. Found: 606.2589.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Chloro-2-((4-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>20</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>11</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Purification was carried out with column chromatography on silica gel with DCM/MeOH (39:1). Yield: 0.112 g, 59%; white crystals; m.p.: 128&#x02013;130 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;110.67 (<italic toggle="yes">c</italic> 0.26 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.53 (dd, <italic toggle="yes">J</italic> = 2.1, 10.2 Hz, 1H), 1.44 (dd, <italic toggle="yes">J</italic> = 1.9, 10.1 Hz, 1H), 1.49 (dq, <italic toggle="yes">J</italic> = 5.4, 12.7 Hz, 1H), 1.69&#x02013;1.65 (1H, m), 1.82 (dt, <italic toggle="yes">J</italic> = 5.2, 12.3 Hz, 1H), 1.91 (dd, <italic toggle="yes">J</italic> = 1.8, 17.3 Hz, 1H), 2.18 (ddd, <italic toggle="yes">J</italic> = 5.8, 5.8, 12.6 Hz, 1H), 2.32 (s, 3H), 2.54 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.64 (dd, <italic toggle="yes">J</italic> = 4.9, 12.3 Hz, 1H), 3.77 (dd, <italic toggle="yes">J</italic> = 5.0, 11.1 Hz, 1H), 4.65 (dd, <italic toggle="yes">J</italic> = 11.0, 14.1 Hz, 1H), 4.76 (s, 1H), 4.82 (dq, <italic toggle="yes">J</italic> = 5.9, 18.6 Hz, 2H), 4.94 (s, 1H), 5.24 (dd, <italic toggle="yes">J</italic> = 5.2, 14.1 Hz, 1H), 6.01 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 6.93 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 6.94 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.11 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.22 (s, 1H), 7.53 (s, 1H), 7.56 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.72 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.98 (s, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.2, 21.9, 30.8, 36.7, 38.8, 48.0, 49.2, 49.4, 51.5, 53.3, 79.7, 104.0, 106.2, 118.4 (2C), 120.4, 122.1 (2C), 123.9, 126.1 (q, <italic toggle="yes">J</italic> = 3.8 Hz, 2C), 127.3, 129.9, 133.3, 139.1, 142.8, 145.0, 145.2, 153.3, 153.8, 157.5, 157.7; <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;61.7; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>32</sub>H<sub>32</sub>ClF<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup>: 622.2309. Found: 622.2293.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((1-methyl-1<italic toggle="yes">H</italic>-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>21</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> (0.12 g, 0.406 mmol), alkyne <bold>12</bold>, and <italic toggle="yes">tert</italic>-BuOH and water (2:1, 18 mL). Purification with silica gel with DCM/MeOH (19:1) gave compound <bold>21</bold>. Yield: 0.099 g, 45%; white crystals; m.p.: 138&#x02013;141 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;78 (<italic toggle="yes">c</italic> 0.28 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.53 (dd, <italic toggle="yes">J</italic> = 1.6, 10.3 Hz, 1H), 1.44 (dd, <italic toggle="yes">J</italic> = 2.0, 10.3 Hz, 1H), 1.51 (dq, <italic toggle="yes">J</italic> = 5.3, 12.7 Hz, 1H), 1.65 (dd, <italic toggle="yes">J</italic> = 5.1, 11.7 Hz, 1H), 1.82 (dt, <italic toggle="yes">J</italic> = 5.2, 12.4 Hz, 1H), 1.91 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.18 (ddd, <italic toggle="yes">J</italic> = 5.7, 5.7, 12.4 Hz, 1H), 2.36 (s, 3H), 2.58 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.65 (dd, <italic toggle="yes">J</italic> = 4.9, 12.3 Hz, 1H), 3.81 (dd, <italic toggle="yes">J</italic> = 4.8, 11.4 Hz, 1H), 3.86 (s, 3H), 4.67 (dd, <italic toggle="yes">J</italic> = 11.6, 13.9 Hz, 1H), 4.84&#x02013;4.71 (3H, m), 4.94 (s, 1H), 5.28 (dd, <italic toggle="yes">J</italic> = 5.0, 14.1 Hz, 1H), 5.73 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 6.83 (s, 1H), 6.93 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H), 6.96 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H), 7.11 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.50 (s, 1H), 7.55 (s, 1H), 7.70 (s, 1H), 7.79 (d, <italic toggle="yes">J</italic> = 3.1 Hz, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.3, 21.9, 30.8, 36.3, 38.9, 39.2, 48.1, 49.2, 49.4, 51.5, 53.3, 79.6, 104.0, 120.4, 121.1, 122.0, 123.4, 127.3, 129.9, 130.9, 133.3, 139.0, 139.1 (d, <italic toggle="yes">J</italic> = 19.5 Hz), 141.2 (d, <italic toggle="yes">J</italic> = 243 Hz), 145.1, 145.7, 152.5 (d, <italic toggle="yes">J</italic> = 12.7 Hz), 153.8, 155.7 (d, <italic toggle="yes">J</italic> = 2.5 Hz); <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;169.8; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>29</sub>H<sub>33</sub>FN<sub>9</sub>O [M + H]<sup>+</sup>: 542.2792. Found: 542.2776.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Chloro-2-((1-methyl-1<italic toggle="yes">H</italic>-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>22</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>13</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Column chromatography on silica gel with DCM/MeOH (19:1) was used for purification. Yield: 0.080 g, 47%; white crystals; m.p.: 165&#x02013;170 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;71.6 (<italic toggle="yes">c</italic> 0.28 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.53 (d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H), 1.45 (dd, <italic toggle="yes">J</italic> = 1.9, 10.2 Hz, 1H), 1.55&#x02013;1.47 (1H, m), 1.65 (dd, <italic toggle="yes">J</italic> = 5.0, 12.0 Hz, 1H), 1.82 (dt, <italic toggle="yes">J</italic> = 5.3, 12.2 Hz, 1H), 1.91 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.21&#x02013;2.14 (1H, m), 2.36 (s, 3H), 2.57 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.65 (dd, <italic toggle="yes">J</italic> = 4.9, 12.4 Hz, 1H), 3.81 (dd, <italic toggle="yes">J</italic> = 4.9, 11.3 Hz, 1H), 3.86 (s, 3H), 4.66 (dd, <italic toggle="yes">J</italic> = 11.7, 13.9 Hz, 1H), 4.85&#x02013;4.72 (3H, m), 4.94 (s, 1H), 5.27 (dd, <italic toggle="yes">J</italic> = 5.0, 14.1 Hz, 1H), 5.92 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 6.89 (s, 1H), 6.93 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 6.96 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.11 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.51 (s, 1H), 7.52 (s, 1H), 7.68 (s, 1H), 7.91 (s, 1H); <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.3, 21.9, 29.7, 30.8, 36.8, 39.2, 48.1, 49.2, 49.4, 51.5, 53.3, 79.6, 103.9, 120.4, 121.4, 122.0, 122.9, 127.3, 129.9, 131.1, 133.3, 139.1, 145.1 (2C), 145.8, 153.4, 153.8, 157.8, 157.9; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>29</sub>H<sub>33</sub>ClN<sub>9</sub>O [M + H]<sup>+</sup>: 558.2497. Found: 558.2486.</p></sec><sec><title>Methyl 4-((5-Fluoro-4-(((1-(((7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-7-hydroxy-1-methyl-8-methylene-5,6,7,8,9,10-hexahydro-4b<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-10-yl)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-4-yl)methyl)amino)pyrimidin-2-yl)amino)benzoate (<bold>23</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>14</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Compound <bold>28</bold> was purified by column chromatography on silica gel with DCM/MeOH (19:1). Yield: 0.143 g, 79%; pale pink crystals; m.p.: 140&#x02013;144 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;89.3 (c 0.15 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.54 (d, <italic toggle="yes">J</italic> = 10.2 Hz, 1H), 1.43 (d, <italic toggle="yes">J</italic> = 10.2 Hz, 1H), 1.50 (dq, <italic toggle="yes">J</italic> = 5.3, 12.8 Hz, 1H), 1.65 (dd, <italic toggle="yes">J</italic> = 4.8, 11.9 Hz, 1H), 1.82 (dt, <italic toggle="yes">J</italic> = 5.2, 12.3 Hz, 1H), 1.90 (d, <italic toggle="yes">J</italic> = 17.0 Hz, 1H), 2.21&#x02013;2.13 (m, 1H), 2.31 (s, 3H), 2.54 (d, <italic toggle="yes">J</italic> = 17.1 Hz, 1H), 2.63 (dd, <italic toggle="yes">J</italic> = 4.8, 12.4 Hz, 1H), 3.75&#x02013;3.69 (m, 1H), 3.85 (s, 3H), 4.65 (dd, <italic toggle="yes">J</italic> = 11.2, 14.0 Hz, 1H), 4.87&#x02013;4.73 (m, 3H), 4.95 (s, 1H), 5.22 (dd, <italic toggle="yes">J</italic> = 5.1, 14.1 Hz, 1H), 5.92 (t, <italic toggle="yes">J</italic> = 6.1 Hz, 1H), 6.92 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 2H), 6.94 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 2H), 7.10 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.34 (s, 1H), 7.57 (s, 1H), 7.68 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H), 7.84 (s, 1H), 7.98 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.2, 21.9, 30.8, 36.2, 38.9, 48.0, 49.2, 49.4, 51.5, 51.8, 53.3, 79.6, 104.0, 117.5 (2C), 120.4, 122.3, 123.1, 127.3, 129.9, 130.8 (2C), 133.3, 139.1, 139.2 (d, <italic toggle="yes">J</italic> = 19.5 Hz), 141.8 (d, <italic toggle="yes">J</italic> = 247.5 Hz), 144.5, 145.1 (2C), 152.4 (d, <italic toggle="yes">J</italic> = 12.0 Hz), 153.7, 155.0 (d, <italic toggle="yes">J</italic> = 2.8 Hz), 166.8; <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;166.7; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>33</sub>H<sub>35</sub>FN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 596.2785. Found: 596.2770.</p></sec><sec><title>Methyl 4-((5-Chloro-4-(((1-(((7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-7-hydroxy-1-methyl-8-methylene-4b,6,7,8,9,10-hexahydro-5<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-10-yl)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-4-yl)methyl)amino)pyrimidin-2-yl)amino)benzoate (<bold>24</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>15</bold> in <italic toggle="yes">i</italic>-PrOH/H<sub>2</sub>O (2:1). Compound <bold>24</bold> was purified by column chromatography on silica gel with DCM/MeOH (19:1). Yield: 0.066 g, 36%; pale yellow crystals; m.p.: 135&#x02013;138 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;81.7 (<italic toggle="yes">c</italic> 0.17 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl3) &#x003b4; (ppm): 0.54 (d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H), 1.43 (d, <italic toggle="yes">J</italic> = 10.4 Hz, 1H), 1.50 (dq, <italic toggle="yes">J</italic> = 5.3, 12.8 Hz, 1H), 1.64 (dd, <italic toggle="yes">J</italic> = 5.2, 12.2 Hz, 1H), 1.82 (dt, <italic toggle="yes">J</italic> = 5.3, 12.3 Hz, 1H), 1.90 (d, <italic toggle="yes">J</italic> = 17.1 Hz, 1H), 2.21&#x02013;2.14 (m, 1H), 2.31 (s, 3H), 2.52 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.62 (dd, <italic toggle="yes">J</italic> = 5.0, 12.4 Hz, 1H), 3.72 (dd, <italic toggle="yes">J</italic> = 5.1, 10.9 Hz, 1H), 3.86 (s, 3H), 4.63 (dd, <italic toggle="yes">J</italic> = 11.1, 14.0 Hz, 1H), 4.90&#x02013;4.74 (m, 3H), 4.94 (s, 1H), 5.21 (dd, <italic toggle="yes">J</italic> = 5.1, 14.1 Hz, 1H), 6.08 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 6.92 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H), 6.94 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H), 7.10 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.38 (s, 1H), 7.54 (s, 1H), 7.68 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.96 (s, 1H), 7.99 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H); <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.2, 21.9, 30.8, 36.7, 38.9, 48.0, 49.2, 49.4, 51.5, 51.8, 53.3, 79.6, 104.0, 117.9 (2C), 120.4, 122.2, 123.4, 127.3, 129.9, 130.8 (2C), 133.3, 139.1 (2C), 144.0, 145.0 (2C), 153.1, 153.7, 157.3, 157.7, 166.7; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>33</sub>H<sub>35</sub>ClN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 612.2490. Found: 612.2478.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,9a<italic toggle="yes">S</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-1-methyl-8-methylene-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-7-ol (<bold>25</bold>)</title><p>The reaction was accomplished starting from <bold>4</bold> and alkyne <bold>16</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Purification by column chromatography on silica gel with DCM/MeOH (19:1) delivered compound <bold>25</bold>. Yield: 0.172 g, 91%; pale yellow crystals; m.p.: 139&#x02013;141 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;87.41 (<italic toggle="yes">c</italic> 0.17 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.44 (d, <italic toggle="yes">J</italic> = 10.2 Hz, 1H), 1.36 (d, <italic toggle="yes">J</italic> = 10.2 Hz, 1H), 1.50 (dq, <italic toggle="yes">J</italic> = 5.3, 12.7 Hz, 1H), 1.68&#x02013;1.59 (m, 1H), 1.81 (dt, <italic toggle="yes">J</italic> = 5.2, 12.2 Hz, 1H), 1.89 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.21&#x02013;2.14 (m, 1H), 2.33 (s, 3H), 2.57 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 2.66 (dd, <italic toggle="yes">J</italic> = 4.7, 12.4 Hz, 1H), 3.08&#x02013;2.97 (m, 4H), 3.64 (dd, <italic toggle="yes">J</italic> = 4.9, 11.1 Hz, 1H), 3.82&#x02013;3.73 (m, 4H), 4.68&#x02013;4.58 (m, 2H), 4.80&#x02013;4.74 (m, 2H), 4.94 (s, 1H), 5.15 (dd, <italic toggle="yes">J</italic> = 4.9, 14.0 Hz, 1H), 5.79 (t, <italic toggle="yes">J</italic> = 6.0 Hz, 1H), 6.78 (s, 1H), 6.88 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), 6.94 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 2H), 6.95 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 2H), 7.11 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.40 (s, 1H), 7.45 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), 7.77 (s, 1H); <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.3, 21.9, 30.8, 36.0, 38.9, 47.9, 49.3 (2C), 50.0 (2C), 51.6, 53.2, 66.8 (2C), 79.6, 104.0, 116.4 (2C), 120.4, 121.8 (2C), 122.9, 127.3, 129.9, 133.0, 133.3, 139.2, 139.5 (d, <italic toggle="yes">J</italic> = 19.3 Hz), 141.4 (d, <italic toggle="yes">J</italic> = 244.5 Hz), 145.1, 145.3, 147.2, 152.2 (d, <italic toggle="yes">J</italic> = 12.3 Hz), 153.8, 156.3 (d, <italic toggle="yes">J</italic> = 2.7 Hz); <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;169.3; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>35</sub>H<sub>40</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 623.3258. Found: 623.3244.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((2-Chloro-5-fluoropyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>26</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>8</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Compound <bold>26</bold> was purified by column chromatography on silica gel with DCM/MeOH (9:1). Yield: 0.040 g, 51%; white crystals; m.p.: 137&#x02013;140 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;6.28 (<italic toggle="yes">c</italic> 0.29 MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 1.20&#x02013;1.12 (m, 2H), 1.53&#x02013;1.42 (m, 3H), 1.70&#x02013;1.62 (m, 2H), 2.15 (s, 3H), 2.20&#x02013;2.17 (m, 1H), 2.63 (dd, <italic toggle="yes">J</italic> = 5.1, 11.8 Hz, 1H), 3.35 (d, <italic toggle="yes">J</italic> = 5.8 Hz, 2H), 3.69 (s, 1H), 3.86 (t, <italic toggle="yes">J</italic> = 6.9 Hz, 1H), 4.08 (s, 1H), 4.26 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 4.69&#x02013;4.54 (m, 3H), 5.16 (dd, <italic toggle="yes">J</italic> = 6.3, 14.3 Hz, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 2H), 6.91 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 2H), 7.05 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 8.12&#x02013;8.10 (m, 2H), 8.65 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.6, 22.3, 33.4, 35.3, 36.1, 45.5, 48.9 (2C), 51.4, 53.6, 63.4, 78.4, 79.2, 120.6, 124.8, 127.1, 129.8, 133.6, 140.4, 140.9, 143.9, 144.7, 145.7, 153.7 (d, <italic toggle="yes">J</italic> = 13.00 Hz), 153.9 (d, <italic toggle="yes">J</italic> = 2.5 Hz). <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>): &#x003b4; (ppm): &#x02212;157.1; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>25</sub>H<sub>29</sub>ClFN<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 515.1974. Found: 515.1960.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((2,5-Dichloropyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>27</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>9</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). The obtained crude product was purified by column chromatography on silica gel with toluene/EtOH (9:1). Yield: 0.055 g, 34%; white crystals; m.p.: 240&#x02013;243 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;3.4 (<italic toggle="yes">c</italic> 0.26 MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 1.20&#x02013;1.13 (m, 2H), 1.55&#x02013;1.45 (m, 3H), 1.71&#x02013;1.63 (m, 2H), 2.14 (s, 3H), 2.20&#x02013;2.17 (m, 1H), 2.63 (dd, <italic toggle="yes">J</italic> = 5.7, 11.7 Hz, 1H), 3.36 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 3.66 (s, 1H), 3.86 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 1H), 4.05 (s, 1H), 4.22 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 4.57 (dd, <italic toggle="yes">J</italic> = 7.8, 14.4 Hz, 1H), 4.66 (ddd, <italic toggle="yes">J</italic> = 6.1, 15.5, 21.9 Hz, 2H), 5.15 (dd, <italic toggle="yes">J</italic> = 6.3, 14.3 Hz, 1H), 6.88 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 6.90 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.05 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 8.08 (s, 1H), 8.19 (s, 1H), 8.38 (t, <italic toggle="yes">J</italic> = 5.9 Hz, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.6, 22.3, 33.4, 35.3, 36.7, 45.5, 48.9 (2C), 51.4, 53.6, 63.4, 78.4, 79.2, 113.5, 120.5, 124.7, 127.1, 129.8, 133.6, 140.9, 144.0, 145.7, 154.4, 157.8, 159.0. HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>25</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 531.1678. Found: 531.1669.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((4-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>28</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>10</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1) mixture. The obtained crude product was purified by column chromatography on silica gel with toluene/EtOH (9:1). Yield: 0.10 g, 52%; white crystals; m.p.: 146&#x02013;148 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +3.2 (<italic toggle="yes">c</italic> 0.27 MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 1.19&#x02013;1.12 (m, 2H), 1.53&#x02013;1.43 (m, 2H), 1.55 (d, <italic toggle="yes">J</italic> = 10.2 Hz, 1H), 1.71&#x02013;1.61 (m, 2H), 2.08 (s, 3H), 2.15 (q, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 2.60 (dd, <italic toggle="yes">J</italic> = 5.5, 11.9 Hz, 1H), 3.36 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 3.72 (s, 1H), 3.84 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 4.09 (s, 1H), 4.25 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 4.55 (dd, <italic toggle="yes">J</italic> = 7.6, 14.3 Hz, 1H), 4.70 (ddt, <italic toggle="yes">J</italic> = 5.9, 14.2, 13.6 Hz, 2H), 5.11 (dd, <italic toggle="yes">J</italic> = 6.4, 14.4 Hz, 1H), 6.85 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.03 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.52 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H), 7.88 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), 7.97 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H), 8.04 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 8.15 (s, 1H), 9.50 (s, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.5, 22.3, 33.5, 35.3, 36.2, 45.4, 48.8, 48.9, 51.4, 53.6, 63.4, 78.4, 79.2, 117.9 (2C), 120.5, 120.5, 120.7, 124.5, 126.0 (d, <italic toggle="yes">J</italic> = 3.6 Hz, 2C), 127.0, 129.7, 133.5, 139.2 (d, <italic toggle="yes">J</italic> = 18.8 Hz), 141.0, 141.8 (d, <italic toggle="yes">J</italic> = 246.1 Hz), 145.1, 145.3, 145.6, 152.4 (d, <italic toggle="yes">J</italic> = 12.5 Hz), 155.7 (d, 2.8 Hz). <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): &#x02212;165.9, &#x02212;59.7 HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>32</sub>H<sub>34</sub>F<sub>4</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 640.2659. Found: 640.2642.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Chloro-2-((4-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>29</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>11</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). The crude product was purified by column chromatography on silica gel with toluene/EtOH (9:1). Yield: 0.072 g, 36%; white crystals; m.p.: 185&#x02013;189 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +11.0 (<italic toggle="yes">c</italic> 0.27 MeOH); <sup>1</sup>H NMR (500 MHz, DMSO) &#x003b4; (ppm): 1.14 (d, <italic toggle="yes">J</italic> = 10.7 Hz, 1H), 1.17 (d, <italic toggle="yes">J</italic> = 13.5 Hz, 1H), 1.52&#x02013;1.43 (m, 2H), 1.57 (d, <italic toggle="yes">J</italic> = 10.7 Hz, 1H), 1.73&#x02013;1.64 (m, 2H), 2.06 (s, 3H), 2.19&#x02013;2.11 (m, 1H), 2.60 (dd, <italic toggle="yes">J</italic> = 5.5, 11.8 Hz, 1H), 3.69 (s, 1H), 3.82 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 4.09 (s, 1H), 4.25 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 4.54 (dd, <italic toggle="yes">J</italic> = 7.5, 14.4 Hz, 1H), 4.72 (ddt, <italic toggle="yes">J</italic> = 5.9, 13.7, 12.9 Hz, 2H), 5.10 (dd, <italic toggle="yes">J</italic> = 6.3, 14.4 Hz, 1H), 6.84 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.03 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.53 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 7.76 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 7.87 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), 8.03 (s, 1H), 8.11 (s, 1H), 9.59 (s, 1H); <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.4, 22.3, 33.4, 35.3, 36.8, 45.4, 48.9 (2C), 51.4, 53.6, 63.4, 78.4, 79.2, 105.3, 118.5 (2C), 120.5, 120.9, 121.2, 124.4, 126.0 (d, <italic toggle="yes">J</italic> = 3.4 Hz, 2C), 127.0, 129.7, 133.5, 140.9, 144.8, 145.2, 145.6, 153.5, 157.8, 158.0; <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>): &#x003b4; (ppm): &#x02212;59.79; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>32</sub>H<sub>34</sub>ClF<sub>3</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 656.2363. Found: 656.2347.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>30</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>12</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Purification was conducted with column chromatography on silica gel with DCM/MeOH (15:1) increased to 100% MeOH. Yield: 0.121 g, 69%; white crystals; m.p.: 200&#x02013;205 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +5.42 (<italic toggle="yes">c</italic> 0.29 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.93 (d, <italic toggle="yes">J</italic> = 10.5 Hz, 1H), 1.19 (d, <italic toggle="yes">J</italic> = 10.7 Hz, 1H), 1.37 (d, <italic toggle="yes">J</italic> = 14.8 Hz, 1H), 1.58&#x02013;1.48 (1H, m), 1.90&#x02013;1.78 (2H, m), 2.30&#x02013;2.22 (1H, m), 2.38 (s, 4H), 2.64 (dd, <italic toggle="yes">J</italic> = 5.5, 11.9 Hz, 1H), 3.55 (d, <italic toggle="yes">J</italic> = 11.4 Hz, 1H), 3.74 (d, <italic toggle="yes">J</italic> = 11.3 Hz, 1H), 3.81 (dd, <italic toggle="yes">J</italic> = 4.9, 11.6 Hz, 1H), 3.85 (s, 3H), 4.61 (dd, <italic toggle="yes">J</italic> = 11.8, 13.9 Hz, 1H), 4.80 (dt, <italic toggle="yes">J</italic> = 6.0, 16.1 Hz, 2H), 5.39 (dd, <italic toggle="yes">J</italic> = 4.8, 14.1 Hz, 1H), 5.77 (t, <italic toggle="yes">J</italic> = 6.1 Hz, 1H), 6.90 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 6.94 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 6.98 (s, 1H), 7.09 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.53 (s, 1H), 7.69 (s, 1H), 7.78&#x02013;7.75 (2H, m). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.4, 22.0, 29.6, 32.7, 34.7, 36.3, 39.1, 45.4, 49.5 (2C), 51.7, 53.1, 64.3, 78.6, 79.9, 120.5, 121.1, 123.5, 123.8, 127.3, 130.0, 133.4, 139.1, 139.2 (d, <italic toggle="yes">J</italic> = 19.4 Hz), 141.2 (d, <italic toggle="yes">J</italic> = 243.2 Hz) 144.7, 145.4, 152.5 (d, <italic toggle="yes">J</italic> = 12.0 Hz), 155.8. <sup>19</sup>F-NMR (470 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): &#x02212;170.0; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>29</sub>H<sub>35</sub>FN<sub>9</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 576.2847. Found: 576.2832.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Chloro-2-((1-methyl-1&#x02032;<italic toggle="yes">H</italic>-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>31</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>13</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Column chromatography on silica gel with DCM/MeOH (6:1) gave compound <bold>31</bold>. Yield: 0.17 g, 95%; white crystals; m.p.: 166&#x02013;170 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +9.9 (<italic toggle="yes">c</italic> 0.19 MeOH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 0.95 (d, <italic toggle="yes">J</italic> = 11.1 Hz, 1H), 1.18 (d, <italic toggle="yes">J</italic> = 11.1 Hz, 1H), 1.39&#x02013;1.32 (1H, m), 1.58&#x02013;1.47 (1H, m), 1.90&#x02013;1.77 (3H, m), 2.30&#x02013;2.22 (1H, m), 2.37 (s, 3H), 2.64 (dd, <italic toggle="yes">J</italic> = 5.5, 11.9 Hz, 1H), 3.55 (d, <italic toggle="yes">J</italic> = 11.5 Hz, 1H), 3.73 (d, <italic toggle="yes">J</italic> = 11.5 Hz, 1H), 3.84&#x02013;3.79 (1H, m), 3.85 (s, 3H), 4.61 (t, <italic toggle="yes">J</italic> = 13.0 Hz, 1H), 4.81 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 5.39 (dd, <italic toggle="yes">J</italic> = 4.8, 14.0 Hz, 1H), 6.05 (s, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 6.94 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.09 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.38&#x02013;7.29 (1H, m), 7.55 (s, 1H), 7.68 (s, 1H), 7.76 (s, 1H), 7.87 (s, 1H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) &#x003b4; (ppm): 21.4, 22.0, 32.8, 34.7, 36.8, 39.2, 45.4, 49.5 (2C), 51.7, 53.1, 64.3, 78.7, 79.9, 120.5 (2C), 121.4, 122.9, 123.9, 127.3, 130.0, 131.1 (2C), 133.4, 139.2, 144.7 (2C), 157.9 (2C); HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>29</sub>H<sub>35</sub>ClN<sub>9</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 592.2551. Found: 592.2540.</p></sec><sec><title>Methyl 4-((4-(((1-(((7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-7,8-Dihydroxy-8-(hydroxymethyl)-1-methyl-4b,6,7,8,9,10-hexahydro-5<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-10-yl)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-4-yl)methyl)amino)-5-fluoropyrimidin-2-yl)amino)benzoate (<bold>32</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>14</bold> in THF/H<sub>2</sub>O (2:1). Purification was conducted with column chromatography on silica gel with DCM/MeOH (19:1). Yield: 0.084 g, 44%; white crystals; m.p.: 251&#x02013;253 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +11.35 (<italic toggle="yes">c</italic> 0.13 DMSO); <sup>1</sup>H NMR (500 MHz, DMSO) &#x003b4; (ppm): 1.19&#x02013;1.12 (m, 2H), 1.53&#x02013;1.41 (m, 2H), 1.58 (d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H), 1.73&#x02013;1.63 (m, 2H), 2.07 (s, 3H), 2.19&#x02013;2.11 (m, 1H), 2.60 (dd, <italic toggle="yes">J</italic> = 5.4, 11.9 Hz, 1H), 3.36 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 3.71 (s, 1H), 3.83&#x02013;3.78 (m, 4H), 4.07 (s, 1H), 4.22 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 4.53 (dd, <italic toggle="yes">J</italic> = 7.4, 14.4 Hz, 1H), 4.70 (dq, <italic toggle="yes">J</italic> = 5.9, 14.0 Hz, 2H), 5.10 (dd, <italic toggle="yes">J</italic> = 6.3, 14.4 Hz, 1H), 6.84 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 6.89 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.03 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.80 (s, 4H), 7.96 (d, <italic toggle="yes">J</italic> = 3.3 Hz, 1H), 8.03 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 8.12 (s, 1H), 9.50 (s, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.5, 22.3, 33.5, 35.3, 36.2, 45.4, 48.9 (2C), 51.4, 52.0, 53.6, 63.4, 78.4, 79.3, 117.5 (2C), 120.5, 121.3, 124.5, 127.0, 129.7, 130.4 (2C), 133.6, 139.3 (d, <italic toggle="yes">J</italic> = 18.9 Hz), 141.0, 141.8 (d, <italic toggle="yes">J</italic> = 246.5 Hz), 145.1, 145.6, 146.2, 152.4 (d, <italic toggle="yes">J</italic> = 12.6 Hz), 155.6 (d, <italic toggle="yes">J</italic> = 2.8 Hz), 166.5; <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): &#x02212;165.6; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>33</sub>H<sub>37</sub>FN7O<sub>5</sub> [M + H]<sup>+</sup>: 630.2840. Found: 630.2825.</p></sec><sec><title>Methyl 4-((5-Chloro-4-(((1-(((7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-7,8-dihydroxy-8-(hydroxymethyl)-1-methyl-4b,6,7,8,9,10-hexahydro-5<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulen-10-yl)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-4-yl)methyl)amino)pyrimidin-2-yl)amino)benzoate (<bold>33</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>15</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). Product <bold>33</bold> precipitated in EtOH was purified by filtration. Yield: 0.084 g, 43%; white crystals; m.p.: 283&#x02013;285 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = +54.1 (<italic toggle="yes">c</italic> 0.13 DMSO); <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 1.20&#x02013;1.12 (m, 2H), 1.53&#x02013;1.41 (m, 2H), 1.60 (d, <italic toggle="yes">J</italic> = 10.4 Hz, 1H), 1.72&#x02013;1.65 (m, 2H), 2.05 (s, 3H), 2.19&#x02013;2.11 (m, 1H), 2.59 (dd, <italic toggle="yes">J</italic> = 5.4, 11.6 Hz, 1H), 3.36 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 2H), 3.70 (s, 1H), 3.79 (s, 4H), 4.07 (s, 1H), 4.22 (t, <italic toggle="yes">J</italic> = 5.5 Hz, 1H), 4.52 (dd, <italic toggle="yes">J</italic> = 7.2, 14.2 Hz, 1H), 4.72 (dq, <italic toggle="yes">J</italic> = 5.8, 14.1 Hz, 2H), 5.08 (dd, <italic toggle="yes">J</italic> = 6.4, 14.4 Hz, 1H), 6.83 (d, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 6.88 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.02 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.83&#x02013;7.74 (m, 5H), 8.04 (s, 1H), 8.09 (s, 1H), 9.63 (s, 1H); <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.4, 22.4, 33.5, 35.3, 36.8, 45.4, 48.8 (2C), 51.4, 52.1, 53.6, 63.5, 78.4, 79.3, 105.3, 118.1 (2C), 120.5, 121.8, 124.4, 127.0, 129.7, 130.4 (2C), 133.6, 141.0, 145.2, 145.6, 145.8, 153.5, 157.8, 157.9, 166.5; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>33</sub>H<sub>37</sub>ClN<sub>7</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 646.2545. Found: 642.2534.</p></sec><sec><title>(7<italic toggle="yes">S</italic>,8<italic toggle="yes">S</italic>,9a<italic toggle="yes">R</italic>,10<italic toggle="yes">R</italic>)-10-((4-(((5-Fluoro-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)amino)methyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)methyl)-8-(hydroxymethyl)-1-methyl-4b,5,6,8,9,10-hexahydro-7<italic toggle="yes">H</italic>-7,9a-methanobenzo[a]azulene-7,8-diol (<bold>34</bold>)</title><p>The reaction was accomplished starting from <bold>5</bold> and alkyne <bold>16</bold> in <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1). The product was isolated after purification by column chromatography on silica gel with DCM/MeOH (19:1 increased to 9:1). Yield: 0.18 g, 92%; pale yellow crystals; m.p.: 121&#x02013;124 &#x000b0;C; [&#x003b1;]<sub>D</sub><sup>20</sup> = &#x02013;3.87 (<italic toggle="yes">c</italic> 0.18 MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 1.20&#x02013;1.13 (m, 2H), 1.52&#x02013;1.42 (m, 2H), 1.57 (d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H), 1.72&#x02013;1.62 (m, 2H), 2.10 (s, 3H), 2.20&#x02013;2.12 (m, 1H), 2.62 (dd, <italic toggle="yes">J</italic> = 5.2, 11.8 Hz, 1H), 2.98&#x02013;2.94 (m, 4H), 3.36 (d, <italic toggle="yes">J</italic> = 5.8 Hz, 2H), 3.71&#x02013;3.67 (m, 5H), 3.80 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 4.08 (s, 1H), 4.22 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 4.53 (dd, <italic toggle="yes">J</italic> = 7.5, 14.3 Hz, 1H), 4.65 (dq, <italic toggle="yes">J</italic> = 5.8, 14.0 Hz, 2H), 5.09 (dd, <italic toggle="yes">J</italic> = 6.3, 14.3 Hz, 1H), 6.80 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H), 6.87 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 6.90 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.04 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.51 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H), 7.77 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 7.84 (d, <italic toggle="yes">J</italic> = 3.5 Hz, 1H), 8.06 (s, 1H), 8.72 (s, 1H). <sup>13</sup>C-NMR (125 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): 20.5, 22.4, 33.5, 35.3, 36.0, 45.4, 48.8 (2C), 49.9 (2C), 53.6, 63.5, 66.6 (2C), 78.5, 79.3, 116.1 (2C), 120.2, 120.5 (2C), 124.6, 127.1, 129.8, 133.6, 134.3, 139.4 (d, <italic toggle="yes">J</italic> = 18.3 Hz), 141.0, 141,2 (d, <italic toggle="yes">J</italic> = 243.6 Hz), 145.2, 145.7 (2C), 146.1, 152.2 (d, <italic toggle="yes">J</italic> = 12.2 Hz), 156.5 (d, <italic toggle="yes">J</italic> = 2.8). <sup>19</sup>F-NMR (470 MHz, DMSO-d<sub>6</sub>) &#x003b4; (ppm): &#x02212;168.5; HRMS (ESI): <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calcd. for C<sub>35</sub>H<sub>42</sub>FN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 657.3313. Found: 657.3294.</p></sec></sec></sec><sec id="sec3dot4-pharmaceuticals-18-00168"><title>3.4. Antimicrobial Analyses</title><p>The synthesized compounds were dissolved in DMSO and diluted with H<sub>2</sub>O to reach concentration levels of up to 100 &#x003bc;g/mL and 10 &#x003bc;g/mL with a final DMSO content of 1%. Then, the resulting solutions were investigated in a microdilution assay using bacterial and yeast strains including <italic toggle="yes">Bacillus subtilis</italic> SZMC 0209 (Gram-positive), <italic toggle="yes">Staphylococcus aureus</italic> SZMC 14,611 (Gram-positive), <italic toggle="yes">Escherichia coli</italic> SZMC 6271 (Gram-negative), and <italic toggle="yes">Pseudomonas aeruginosa</italic> SZMC 23,290 (Gram-negative) as well as <italic toggle="yes">Candida albicans</italic> SZMC 1533 and <italic toggle="yes">C. krusei</italic> SZMC 1352, respectively, according to the M07-A10 CLSI guideline [<xref rid="B39-pharmaceuticals-18-00168" ref-type="bibr">39</xref>] and our previous work [<xref rid="B47-pharmaceuticals-18-00168" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceuticals-18-00168" ref-type="bibr">48</xref>]. The microbe suspensions were prepared from fresh cultures cultivated overnight in different fermentation broths for both bacteria (10 g/L peptone, 5 g/L NaCl, 5 g/L yeast extract) and yeast (20 g/L peptone, 10 g/L yeast extract, 20 g/L glucose) at 37 &#x000b0;C, and their concentrations were set to 4 &#x000d7; 10<sup>5</sup> cells/mL with sterile media. After that, 100 &#x003bc;L of suspension containing the bacterial or yeast cells and 100 &#x003bc;L of the test solutions were dispensed into each well of 96-well plates and incubated for 24 h at 37 &#x000b0;C and 32 &#x000b0;C for bacteria and yeasts, respectively. The blank sample was a mixture of 100 &#x003bc;L broth and 100 &#x003bc;L of a test solution used for background correction, while 100 &#x003bc;L of microbial suspension supplemented with 100 &#x003bc;L of 1% DMSO was applied as a negative control. For the positive control, ampicillin (Sigma, Kawasaki, Japan) or nystatin (Sigma) was applied for bacteria or fungi, respectively, at two final concentration levels (50 &#x003bc;g/mL and 5 &#x003bc;g/mL). The inhibitory effects were calculated as the percentage of the negative control after blank correction using the following formula: inhibitory effect (%) = 100 &#x02212; ((OD<sub>test</sub> &#x02212; OD<sub>blank</sub>)/OD<sub>negative</sub>) &#x000d7; 100). Here, OD<sub>test</sub> represents the OD values of the test solution, OD<sub>negative</sub> represents the OD values of the negative control, and OD<sub>blank</sub> represents the OD values of blank samples.</p></sec><sec id="sec3dot5-pharmaceuticals-18-00168"><title>3.5. General Procedure for Molecular Docking</title><p>Protein structures were obtained from the Protein Data Bank (PDB code: 6M1S, resolution 2.25 &#x000c5;). Protein preparation steps, including the removal of water molecules, addition of polar hydrogens, and assignment of Kollman charges, were carried out using AutoDock Tools 1.5.7 [<xref rid="B49-pharmaceuticals-18-00168" ref-type="bibr">49</xref>]. The energy minimization of the protein structures was performed using Chimera 1.18. The grid box was centered on the co-crystallized native ligand&#x02019;s coordinates (X = 22.036, Y = 1.330, Z = 41.041) with dimensions of 30 &#x000d7; 30 &#x000d7; 30 &#x000c5;. Ligand structures were drawn in ChemDraw 16.0, optimized, and prepared using AutoDock Tools. Docking simulations were conducted using AutoDock Vina [<xref rid="B40-pharmaceuticals-18-00168" ref-type="bibr">40</xref>] with the protein kept rigid and the ligand flexible. Validation involved redocking the native co-crystallized ligand, achieving RMSD values below 3.0 &#x000c5; for the top 5 scored compounds [<xref rid="B50-pharmaceuticals-18-00168" ref-type="bibr">50</xref>]. The docking results were visualized and analyzed using Discovery Studio (version 16.0, BIOVIA, San Diego, CA, USA, Dassault Syst&#x000e8;mes), which also generated 3D and 2D interaction diagrams.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00168"><title>4. Conclusions</title><p>A series of gibberellic acid-based 2,4-diaminopyrimidines was designed and synthesized from commercially available gibberellic acid. The antimicrobial activity of the prepared compounds was explored in <italic toggle="yes">B. subtilis</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli</italic>, and <italic toggle="yes">P. aeruginosa</italic> bacteria, as well as in <italic toggle="yes">C. krusei</italic> and <italic toggle="yes">C. albicans</italic> fungi. The best diaminopyrimidine derivative <bold>29</bold> with 5-chloro and 2-((4-(trifluoromethyl)phenyl)amino substituents showed reliable antimicrobial activities against both <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">C. krusei</italic> and was proven to be an excellent lead molecule for further investigation. Similarly, compound <bold>20</bold> expressed a selective antibacterial effect against <italic toggle="yes">P. aeruginosa</italic>, while compound <bold>28</bold> was effectively selective against fungus. The <italic toggle="yes">P. aeruginosa</italic> DNA gyrase inhibitor activity of compounds <bold>20</bold> and <bold>29</bold>, as a possible pathway, was examined by molecular interactions between the active compounds and their potential targets using molecular docking studies, which were conducted using the AutoDock Vina program.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful for financial support from the Hungarian Research Foundation and the Ministry of Innovation and Technology of Hungary. The high-resolution mass spectrometric analysis was performed by Robert Berkecz.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00168"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020168/s1">https://www.mdpi.com/article/10.3390/ph18020168/s1</uri>: Figures S1&#x02013;S131: <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR, COSY, NOESY, HSQC, and HMBC spectra of new compounds; Figures S132&#x02013;S134 and Tables S1&#x02013;S4: docking study; Figure S135: 2D-diagram showing interactions between the best pose of compound <bold>30</bold> and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S); Figure S136: 3D presentation showing the binding location and accumulated poses predicted by the software of the original ligand and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S); Figure S137: 3D presentation showing the binding location and accumulated poses predicted by the software of compounds <bold>20</bold> and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S); Figure S138: 3D presentation showing the binding location and accumulated poses predicted by the software of compounds <bold>29</bold> and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S); Figure S139: 3D presentation showing the binding location and accumulated poses predicted by the software of compounds <bold>30</bold> and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S).</p><supplementary-material id="pharmaceuticals-18-00168-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00168-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Z.S. and A.S. conceived and designed the experiments; D.D. and N.R.S. performed the experiments, analyzed the data, and wrote the experimental part; Z.S., D.D. and A.S. discussed the results and contributed to writing this paper. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article and <xref rid="app1-pharmaceuticals-18-00168" ref-type="app">Supplementary Material</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of this manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDPI</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidisciplinary Digital Publishing Institute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOAJ</td><td align="left" valign="middle" rowspan="1" colspan="1">Directory of open access journals</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLA</td><td align="left" valign="middle" rowspan="1" colspan="1">Three-letter acronym</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LD</td><td align="left" valign="middle" rowspan="1" colspan="1">Linear dichroism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CuAAC reaction</td><td align="left" valign="middle" rowspan="1" colspan="1">Copper-catalyzed azide&#x02013;alkyne cycloaddition</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCM</td><td align="left" valign="middle" rowspan="1" colspan="1">Dichloromethane</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DIPEA</td><td align="left" valign="middle" rowspan="1" colspan="1">N,N-Diisopropylethylamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMAP</td><td align="left" valign="middle" rowspan="1" colspan="1">4-(Dimethylamino)pyridine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMSO</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethyl sulfoxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MW </td><td align="left" valign="middle" rowspan="1" colspan="1">Microwave </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMO</td><td align="left" valign="middle" rowspan="1" colspan="1">4-Methylmorpholine N-oxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOE</td><td align="left" valign="middle" rowspan="1" colspan="1">Nuclear Overhauser effect</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SZMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Szeged Microbiology Collection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Triethylamine</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00168"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murray</surname><given-names>C.J.L.</given-names></name>
<name><surname>Ikuta</surname><given-names>K.S.</given-names></name>
<name><surname>Sharara</surname><given-names>F.</given-names></name>
<name><surname>Swetschinski</surname><given-names>L.</given-names></name>
<name><surname>Robles Aguilar</surname><given-names>G.</given-names></name>
<name><surname>Gray</surname><given-names>A.</given-names></name>
<name><surname>Han</surname><given-names>C.</given-names></name>
<name><surname>Bisignano</surname><given-names>C.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Wool</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00168"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>European Centre for Disease Prevention and Control</collab>
</person-group><source>Antimicrobial Resistance in the EU/EEA (EARS-Net)&#x02014;Annual Epidemiological Report 2023</source><publisher-name>ECDC</publisher-name><publisher-loc>Stockholm, Sweden</publisher-loc><year>2024</year></element-citation></ref><ref id="B3-pharmaceuticals-18-00168"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farha</surname><given-names>M.A.</given-names></name>
<name><surname>Brown</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Drug Repurposing for Antimicrobial Discovery</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>565</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0357-1</pub-id><pub-id pub-id-type="pmid">30833727</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00168"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaou</surname><given-names>N.</given-names></name>
<name><surname>Stavropoulou</surname><given-names>E.</given-names></name>
<name><surname>Voidarou</surname><given-names>C.</given-names></name>
<name><surname>Tsigalou</surname><given-names>C.</given-names></name>
<name><surname>Bezirtzoglou</surname><given-names>E.</given-names></name>
</person-group><article-title>Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>2041</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9102041</pub-id><pub-id pub-id-type="pmid">34683362</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00168"><label>5.</label><element-citation publication-type="book"><source>Plant Bioactives and Drug Discovery: Principles, Practice, and Perspectives</source><person-group person-group-type="editor">
<name><surname>Cechinel-Filho</surname><given-names>V.</given-names></name>
</person-group><series>Wiley Series in Drug Discovery and Development</series><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2012</year><isbn>978-0-470-58226-8</isbn></element-citation></ref><ref id="B6-pharmaceuticals-18-00168"><label>6.</label><element-citation publication-type="book"><source>Studies in Natural Products Chemistry</source><person-group person-group-type="editor">
<name><surname>Rahman</surname><given-names>A.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><publisher-loc>New York, NY, USA</publisher-loc><year>1988</year><isbn>978-0-444-42970-4</isbn></element-citation></ref><ref id="B7-pharmaceuticals-18-00168"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>D.J.</given-names></name>
<name><surname>Cragg</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Natural Products as Sources of New Drugs from 1981 to 2014</article-title><source>J. Nat. Prod.</source><year>2016</year><volume>79</volume><fpage>629</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b01055</pub-id><pub-id pub-id-type="pmid">26852623</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00168"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schreiber</surname><given-names>K.</given-names></name>
<name><surname>Schneider</surname><given-names>G.</given-names></name>
<name><surname>Sembdner</surname><given-names>G.</given-names></name>
</person-group><article-title>Gibberelline&#x02014;XII</article-title><source>Tetrahedron</source><year>1968</year><volume>24</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/0040-4020(68)89010-6</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-18-00168"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>J.R.</given-names></name>
</person-group><article-title>The Chemistry of the Gibberellins</article-title><source>Nat. Prod. Rep.</source><year>1990</year><volume>7</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1039/np9900700041</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-18-00168"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mander</surname><given-names>L.N.</given-names></name>
</person-group><article-title>The Chemistry of Gibberellins: An Overview</article-title><source>Chem. Rev.</source><year>1992</year><volume>92</volume><fpage>573</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1021/cr00012a005</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-18-00168"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.-Y.</given-names></name>
<name><surname>Kuo</surname><given-names>S.-R.</given-names></name>
<name><surname>Chien</surname><given-names>C.-T.</given-names></name>
</person-group><article-title>Roles of Gibberellins and Abscisic Acid in Dormancy and Germination of Red Bayberry (Myrica Rubra) Seeds</article-title><source>Tree Physiol.</source><year>2008</year><volume>28</volume><fpage>1431</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1093/treephys/28.9.1431</pub-id><pub-id pub-id-type="pmid">18595855</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00168"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alabdeen Khdar</surname><given-names>Z.</given-names></name>
<name><surname>Le</surname><given-names>T.M.</given-names></name>
<name><surname>Szakonyi</surname><given-names>Z.</given-names></name>
</person-group><article-title>Gibberellic Acid (GA<sub>3</sub>): A Versatile Chiral Building Block for Syntheses of Pharmaceutical Agents</article-title><source>Chem. Biodivers.</source><year>2024</year><volume>22</volume><elocation-id>e202401823</elocation-id><pub-id pub-id-type="doi">10.1002/cbdv.202401823</pub-id><pub-id pub-id-type="pmid">39307688</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00168"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Qing</surname><given-names>C.</given-names></name>
</person-group><article-title>Antitumor and Antiangiogenic Effects of GA-13315, a Gibberellin Derivative</article-title><source>Investig. New Drug.</source><year>2012</year><volume>30</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9501-8</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-18-00168"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Luo</surname><given-names>F.</given-names></name>
<name><surname>Sun</surname><given-names>P.-H.</given-names></name>
</person-group><article-title>Synthesis and Antitumor Activity of Novel Gibberellin Derivatives with Tetracyclic Diterpenoid Skeletons</article-title><source>Med. Chem. Res.</source><year>2020</year><volume>29</volume><fpage>1341</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1007/s00044-020-02551-2</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-18-00168"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Annand</surname><given-names>J.R.</given-names></name>
<name><surname>Henderson</surname><given-names>A.R.</given-names></name>
<name><surname>Cole</surname><given-names>K.S.</given-names></name>
<name><surname>Maurais</surname><given-names>A.J.</given-names></name>
<name><surname>Becerra</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Weerapana</surname><given-names>E.</given-names></name>
<name><surname>Koehler</surname><given-names>A.N.</given-names></name>
<name><surname>Mapp</surname><given-names>A.K.</given-names></name>
<name><surname>Schindler</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Gibberellin JRA-003: A Selective Inhibitor of Nuclear Translocation of IKK&#x003b1;</article-title><source>ACS Med. Chem. Lett.</source><year>2020</year><volume>11</volume><fpage>1913</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.9b00613</pub-id><pub-id pub-id-type="pmid">33062173</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00168"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balkwill</surname><given-names>F.</given-names></name>
<name><surname>Mantovani</surname><given-names>A.</given-names></name>
</person-group><article-title>Inflammation and Cancer: Back to Virchow?</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id><pub-id pub-id-type="pmid">11229684</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00168"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coussens</surname><given-names>L.M.</given-names></name>
<name><surname>Werb</surname><given-names>Z.</given-names></name>
</person-group><article-title>Inflammation and Cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/nature01322</pub-id><pub-id pub-id-type="pmid">12490959</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00168"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khdar</surname><given-names>Z.A.</given-names></name>
<name><surname>Le</surname><given-names>T.M.</given-names></name>
<name><surname>Schelz</surname><given-names>Z.</given-names></name>
<name><surname>Zupk&#x000f3;</surname><given-names>I.</given-names></name>
<name><surname>Szakonyi</surname><given-names>Z.</given-names></name>
</person-group><article-title>Stereoselective Synthesis and Antiproliferative Activity of <italic toggle="yes">Allo</italic> -Gibberic Acid-Based 1,3-Aminoalcohol Regioisomers</article-title><source>RSC Med. Chem.</source><year>2024</year><volume>15</volume><fpage>874</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1039/D3MD00665D</pub-id><pub-id pub-id-type="pmid">38516597</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00168"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khdar</surname><given-names>Z.A.</given-names></name>
<name><surname>Le</surname><given-names>T.M.</given-names></name>
<name><surname>Schelz</surname><given-names>Z.</given-names></name>
<name><surname>Zupk&#x000f3;</surname><given-names>I.</given-names></name>
<name><surname>Szakonyi</surname><given-names>Z.</given-names></name>
</person-group><article-title>Stereoselective Synthesis and Application of Gibberellic Acid-Derived Aminodiols</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>10366</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231810366</pub-id><pub-id pub-id-type="pmid">36142293</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00168"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khdar</surname><given-names>Z.A.</given-names></name>
<name><surname>Le</surname><given-names>T.M.</given-names></name>
<name><surname>Schelz</surname><given-names>Z.</given-names></name>
<name><surname>Zupk&#x000f3;</surname><given-names>I.</given-names></name>
<name><surname>Szakonyi</surname><given-names>Z.</given-names></name>
</person-group><article-title>Aminodiols, Aminotetraols and 1,2,3-Triazoles Based on <italic toggle="yes">Allo</italic> -Gibberic Acid: Stereoselective Syntheses and Antiproliferative Activities</article-title><source>RSC Adv.</source><year>2024</year><volume>14</volume><fpage>36698</fpage><lpage>36712</lpage><pub-id pub-id-type="doi">10.1039/D4RA07334G</pub-id><pub-id pub-id-type="pmid">39559570</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00168"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>M.-J.</given-names></name>
<name><surname>Wu</surname><given-names>D.-M.</given-names></name>
<name><surname>Chen</surname><given-names>J.-B.</given-names></name>
<name><surname>Zhao</surname><given-names>J.-F.</given-names></name>
<name><surname>Gong</surname><given-names>L.</given-names></name>
<name><surname>Gong</surname><given-names>Y.-X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>X.-D.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
</person-group><article-title>Synthesis and Anti-Proliferative Activity of Allogibberic Acid Derivatives Containing 1,2,3-Triazole Pharmacophore</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2018</year><volume>28</volume><fpage>2543</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.05.038</pub-id><pub-id pub-id-type="pmid">29884535</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00168"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richter</surname><given-names>M.F.</given-names></name>
<name><surname>Drown</surname><given-names>B.S.</given-names></name>
<name><surname>Riley</surname><given-names>A.P.</given-names></name>
<name><surname>Garcia</surname><given-names>A.</given-names></name>
<name><surname>Shirai</surname><given-names>T.</given-names></name>
<name><surname>Svec</surname><given-names>R.L.</given-names></name>
<name><surname>Hergenrother</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Predictive Compound Accumulation Rules Yield a Broad-Spectrum Antibiotic</article-title><source>Nature</source><year>2017</year><volume>545</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/nature22308</pub-id><pub-id pub-id-type="pmid">28489819</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00168"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Sayed</surname><given-names>M.Y.</given-names></name>
<name><surname>Fetooh</surname><given-names>H.</given-names></name>
<name><surname>Refat</surname><given-names>M.S.</given-names></name>
<name><surname>Eldaroti</surname><given-names>H.H.</given-names></name>
<name><surname>Adam</surname><given-names>A.M.A.</given-names></name>
<name><surname>Saad</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Complexes of the Plant Hormone Gibberellic Acid with the Pt(II), Au(III), Ru(III), V(III), and Se(IV) Ions: Preparation, Characterization, and in Vitro Evaluation of Biological Activity</article-title><source>J. Mol. Liq.</source><year>2019</year><volume>296</volume><fpage>111895</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2019.111895</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-18-00168"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toner</surname><given-names>P.</given-names></name>
<name><surname>Nelson</surname><given-names>D.</given-names></name>
<name><surname>Rao</surname><given-names>J.R.</given-names></name>
<name><surname>Ennis</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>J.E.</given-names></name>
<name><surname>Schock</surname><given-names>B.</given-names></name>
</person-group><article-title>Antimicrobial Properties of Phytohormone (Gibberellins) against Phytopathogens and Clinical Pathogens</article-title><source>Access Microbiol.</source><year>2021</year><volume>3</volume><elocation-id>000278</elocation-id><pub-id pub-id-type="doi">10.1099/acmi.0.000278</pub-id><pub-id pub-id-type="pmid">34816094</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00168"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Then</surname><given-names>R.L.</given-names></name>
</person-group><article-title>History and Future of Antimicrobial Diaminopyrimidines</article-title><source>J. Chemother.</source><year>1993</year><volume>5</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1080/1120009X.1993.11741082</pub-id><pub-id pub-id-type="pmid">8195827</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00168"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landi</surname><given-names>G.</given-names></name>
<name><surname>Linciano</surname><given-names>P.</given-names></name>
<name><surname>Tassone</surname><given-names>G.</given-names></name>
<name><surname>Costi</surname><given-names>M.P.</given-names></name>
<name><surname>Mangani</surname><given-names>S.</given-names></name>
<name><surname>Pozzi</surname><given-names>C.</given-names></name>
</person-group><article-title>High-Resolution Crystal Structure of <italic toggle="yes">Trypanosoma Brucei</italic> Pteridine Reductase 1 in Complex with an Innovative Tricyclic-Based Inhibitor</article-title><source>Acta Crystallogr. D Struct. Biol.</source><year>2020</year><volume>76</volume><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1107/S2059798320004891</pub-id><pub-id pub-id-type="pmid">32496217</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00168"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jadhav</surname><given-names>M.</given-names></name>
<name><surname>Sankhe</surname><given-names>K.</given-names></name>
<name><surname>Bhandare</surname><given-names>R.R.</given-names></name>
<name><surname>Edis</surname><given-names>Z.</given-names></name>
<name><surname>Bloukh</surname><given-names>S.H.</given-names></name>
<name><surname>Khan</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>5170</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26175170</pub-id><pub-id pub-id-type="pmid">34500603</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00168"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahapatra</surname><given-names>A.</given-names></name>
<name><surname>Prasad</surname><given-names>T.</given-names></name>
<name><surname>Sharma</surname><given-names>T.</given-names></name>
</person-group><article-title>Pyrimidine: A Review on Anticancer Activity with Key Emphasis on SAR</article-title><source>Futur. J. Pharm. Sci.</source><year>2021</year><volume>7</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1186/s43094-021-00274-8</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-18-00168"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>R.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Mehndiratta</surname><given-names>S.</given-names></name>
<name><surname>Bedi</surname><given-names>P.</given-names></name>
<name><surname>Nepali</surname><given-names>K.</given-names></name>
</person-group><article-title>Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent Literature</article-title><source>Recent Pat. Anti-Canc.</source><year>2014</year><volume>10</volume><fpage>23</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2174/1574892809666140917104502</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-18-00168"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>VanRheenen</surname><given-names>V.</given-names></name>
<name><surname>Cha</surname><given-names>D.Y.</given-names></name>
<name><surname>Hartley</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Catalytic Osmium Tetroxide Oxidation of Olefins: <italic toggle="yes">Cis</italic> -1,2-Cyclohexanediol</article-title><source>Organic Syntheses</source><person-group person-group-type="editor">
<name><surname>Kende</surname><given-names>A.S.</given-names></name>
<name><surname>Freeman</surname><given-names>J.P.</given-names></name>
</person-group><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2003</year><fpage>43</fpage><isbn>978-0-471-26422-4</isbn></element-citation></ref><ref id="B31-pharmaceuticals-18-00168"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lagoja</surname><given-names>I.</given-names></name>
</person-group><article-title>Pyrimidine as Constituent of Natural Biologically Active Compounds</article-title><source>Chem. Biodivers.</source><year>2005</year><volume>2</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200490173</pub-id><pub-id pub-id-type="pmid">17191918</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00168"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bamou</surname><given-names>F.Z.</given-names></name>
<name><surname>Le</surname><given-names>T.M.</given-names></name>
<name><surname>Tayeb</surname><given-names>B.A.</given-names></name>
<name><surname>Tahaei</surname><given-names>S.A.S.</given-names></name>
<name><surname>Minorics</surname><given-names>R.</given-names></name>
<name><surname>Zupk&#x000f3;</surname><given-names>I.</given-names></name>
<name><surname>Szakonyi</surname><given-names>Z.</given-names></name>
</person-group><article-title>Antiproliferative Activity of (&#x02212;)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives</article-title><source>ChemistryOpen</source><year>2022</year><volume>11</volume><elocation-id>e202200169</elocation-id><pub-id pub-id-type="doi">10.1002/open.202200169</pub-id><pub-id pub-id-type="pmid">36200514</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00168"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nammalwar</surname><given-names>B.</given-names></name>
<name><surname>Bunce</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Recent Advances in Pyrimidine-Based Drugs</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>104</elocation-id><pub-id pub-id-type="doi">10.3390/ph17010104</pub-id><pub-id pub-id-type="pmid">38256937</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00168"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rauckman</surname><given-names>B.S.</given-names></name>
<name><surname>Tidwell</surname><given-names>M.Y.</given-names></name>
<name><surname>Johnson</surname><given-names>J.V.</given-names></name>
<name><surname>Roth</surname><given-names>B.</given-names></name>
</person-group><article-title>2,4-Diamino-5-Benzylpyrimidines and Analogs as Antibacterial Agents. 10. 2,4-Diamino-5-(6-Quinolylmethyl)- and -[(Tetrahydro-6-Quinolyl)Methyl]Pyrimidine Derivatives. Further Specificity Studies</article-title><source>J. Med. Chem.</source><year>1989</year><volume>32</volume><fpage>1927</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1021/jm00128a040</pub-id><pub-id pub-id-type="pmid">2502632</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00168"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perales</surname><given-names>J.B.</given-names></name>
<name><surname>Freeman</surname><given-names>J.</given-names></name>
<name><surname>Bacchi</surname><given-names>C.J.</given-names></name>
<name><surname>Bowling</surname><given-names>T.</given-names></name>
<name><surname>Don</surname><given-names>R.</given-names></name>
<name><surname>Gaukel</surname><given-names>E.</given-names></name>
<name><surname>Mercer</surname><given-names>L.</given-names></name>
<name><surname>Moore Iii</surname><given-names>J.A.</given-names></name>
<name><surname>Nare</surname><given-names>B.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>SAR of 2-Amino and 2,4-Diamino Pyrimidines with in Vivo Efficacy against Trypanosoma Brucei</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>2816</fpage><lpage>2819</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.03.097</pub-id><pub-id pub-id-type="pmid">21507639</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00168"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mercer</surname><given-names>L.</given-names></name>
<name><surname>Bowling</surname><given-names>T.</given-names></name>
<name><surname>Perales</surname><given-names>J.</given-names></name>
<name><surname>Freeman</surname><given-names>J.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.</given-names></name>
<name><surname>Bacchi</surname><given-names>C.</given-names></name>
<name><surname>Yarlett</surname><given-names>N.</given-names></name>
<name><surname>Don</surname><given-names>R.</given-names></name>
<name><surname>Jacobs</surname><given-names>R.</given-names></name>
<name><surname>Nare</surname><given-names>B.</given-names></name>
</person-group><article-title>2,4-Diaminopyrimidines as Potent Inhibitors of Trypanosoma Brucei and Identification of Molecular Targets by a Chemical Proteomics Approach</article-title><source>PLoS Negl. Trop. Dis.</source><year>2011</year><volume>5</volume><elocation-id>e956</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000956</pub-id><pub-id pub-id-type="pmid">21347454</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00168"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rostovtsev</surname><given-names>V.V.</given-names></name>
<name><surname>Green</surname><given-names>L.G.</given-names></name>
<name><surname>Fokin</surname><given-names>V.V.</given-names></name>
<name><surname>Sharpless</surname><given-names>K.B.</given-names></name>
</person-group><article-title>A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective &#x0201c;Ligation&#x0201d; of Azides and Terminal Alkynes</article-title><source>Angew. Chem.</source><year>2002</year><volume>114</volume><fpage>2708</fpage><lpage>2711</lpage><pub-id pub-id-type="doi">10.1002/1521-3757(20020715)114:14&#x0003c;2708::AID-ANGE2708&#x0003e;3.0.CO;2-0</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-18-00168"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Brassard</surname><given-names>C.J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Guha</surname><given-names>P.M.</given-names></name>
<name><surname>Clark</surname><given-names>R.J.</given-names></name>
</person-group><article-title>On the Mechanism of Copper(I)-Catalyzed Azide-Alkyne Cycloaddition</article-title><source>Chem. Rec.</source><year>2016</year><volume>16</volume><fpage>1501</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1002/tcr.201600002</pub-id><pub-id pub-id-type="pmid">27216993</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00168"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</article-title><source>Clinical and Laboratory</source><edition>11th ed.</edition><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2018</year></element-citation></ref><ref id="B40-pharmaceuticals-18-00168"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trott</surname><given-names>O.</given-names></name>
<name><surname>Olson</surname><given-names>A.J.</given-names></name>
</person-group><article-title>AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</article-title><source>J. Comput. Chem.</source><year>2010</year><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00168"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajakumari</surname><given-names>K.</given-names></name>
<name><surname>Aravind</surname><given-names>K.</given-names></name>
<name><surname>Balamugundhan</surname><given-names>M.</given-names></name>
<name><surname>Jagadeesan</surname><given-names>M.</given-names></name>
<name><surname>Somasundaram</surname><given-names>A.</given-names></name>
<name><surname>Brindha Devi</surname><given-names>P.</given-names></name>
<name><surname>Ramasamy</surname><given-names>P.</given-names></name>
</person-group><article-title>Comprehensive Review of DNA Gyrase as Enzymatic Target for Drug Discovery and Development</article-title><source>Eur. J. Med. Chem. Res.</source><year>2024</year><volume>12</volume><fpage>100233</fpage><pub-id pub-id-type="doi">10.1016/j.ejmcr.2024.100233</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-18-00168"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahul</surname><given-names>H.P.</given-names></name>
<name><surname>Solapure</surname><given-names>S.</given-names></name>
<name><surname>Mukherjee</surname><given-names>K.</given-names></name>
<name><surname>Nandi</surname><given-names>V.</given-names></name>
<name><surname>Waterson</surname><given-names>D.</given-names></name>
<name><surname>Shandil</surname><given-names>R.</given-names></name>
<name><surname>Balganesh</surname><given-names>M.</given-names></name>
<name><surname>Sambandamurthy</surname><given-names>V.K.</given-names></name>
<name><surname>Raichurkar</surname><given-names>A.K.</given-names></name>
<name><surname>Deshpande</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1128/AAC.01751-13</pub-id><pub-id pub-id-type="pmid">24126580</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00168"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>V.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names></name>
</person-group><article-title>Designing of Kinase Hinge Binders: A Medicinal Chemistry Perspective</article-title><source>Chem. Biol. Drug Des.</source><year>2022</year><volume>100</volume><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1111/cbdd.14024</pub-id><pub-id pub-id-type="pmid">35112799</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00168"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Ren</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Ding</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Discovery of Pyrido [2,3-<italic toggle="yes">b</italic>] Indole Derivatives with Gram-Negative Activity Targeting Both DNA Gyrase and Topoisomerase IV</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>9623</fpage><lpage>9649</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00768</pub-id><pub-id pub-id-type="pmid">32787097</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00168"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novais</surname><given-names>J.S.</given-names></name>
<name><surname>Campos</surname><given-names>V.R.</given-names></name>
<name><surname>Silva</surname><given-names>A.C.J.A.</given-names></name>
<name><surname>De Souza</surname><given-names>M.C.B.V.</given-names></name>
<name><surname>Ferreira</surname><given-names>V.F.</given-names></name>
<name><surname>Keller</surname><given-names>V.G.L.</given-names></name>
<name><surname>Ferreira</surname><given-names>M.O.</given-names></name>
<name><surname>Dias</surname><given-names>F.R.F.</given-names></name>
<name><surname>Vitorino</surname><given-names>M.I.</given-names></name>
<name><surname>Sathler</surname><given-names>P.C.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and Antimicrobial Evaluation of Promising 7-Arylamino-5,8-Dioxo-5,8-Dihydroisoquinoline-4-Carboxylates and Their Halogenated Amino Compounds for Treating Gram-Negative Bacterial Infections</article-title><source>RSC Adv.</source><year>2017</year><volume>7</volume><fpage>18311</fpage><lpage>18320</lpage><pub-id pub-id-type="doi">10.1039/C7RA00825B</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-18-00168"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Wei</surname><given-names>S.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Zhai</surname><given-names>X.</given-names></name>
</person-group><article-title>Pyrroformyl-Containing 2,4-Diaminopyrimidine Derivatives as a New Optimization Strategy of ALK Inhibitors Combating Mutations</article-title><source>Bioorg. Med. Chem.</source><year>2020</year><volume>28</volume><elocation-id>115715</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115715</pub-id><pub-id pub-id-type="pmid">33069079</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00168"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brocksom</surname><given-names>T.J.</given-names></name>
<name><surname>dos Santos</surname><given-names>R.B.</given-names></name>
<name><surname>Varanda</surname><given-names>N.A.</given-names></name>
<name><surname>Brocksom</surname><given-names>U.</given-names></name>
</person-group><article-title>An Efficient Synthesis of Monoterpene &#x003b1;-Methylene-&#x003b3;-Butyrolactones</article-title><source>Synth. Commun.</source><year>1988</year><volume>18</volume><fpage>1403</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1080/00397918808078810</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-18-00168"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e9;ni</surname><given-names>Z.</given-names></name>
<name><surname>D&#x000e9;k&#x000e1;ny</surname><given-names>M.</given-names></name>
<name><surname>Kov&#x000e1;cs</surname><given-names>B.</given-names></name>
<name><surname>Csupor-L&#x000f6;ffler</surname><given-names>B.</given-names></name>
<name><surname>Zomborszki</surname><given-names>Z.P.</given-names></name>
<name><surname>Kerekes</surname><given-names>E.</given-names></name>
<name><surname>Szekeres</surname><given-names>A.</given-names></name>
<name><surname>Urb&#x000e1;n</surname><given-names>E.</given-names></name>
<name><surname>Hohmann</surname><given-names>J.</given-names></name>
<name><surname>V&#x000e1;nyol&#x000f3;s</surname><given-names>A.</given-names></name>
</person-group><article-title>Bioactivity-Guided Isolation of Antimicrobial and Antioxidant Metabolites from the Mushroom Tapinella Atrotomentosa</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>1082</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23051082</pub-id><pub-id pub-id-type="pmid">29734648</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00168"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Morais Oliveira-Tintino</surname><given-names>C.D.</given-names></name>
<name><surname>Da Silva</surname><given-names>F.E.F.</given-names></name>
<name><surname>Santiago</surname><given-names>G.M.P.</given-names></name>
<name><surname>Das</surname><given-names>C.L.</given-names></name>
<name><surname>Pinto</surname><given-names>F.</given-names></name>
<name><surname>Pessoa</surname><given-names>O.D.L.</given-names></name>
<name><surname>Da Fonseca</surname><given-names>A.M.</given-names></name>
<name><surname>Paulo</surname><given-names>C.L.R.</given-names></name>
<name><surname>Dos Santos</surname><given-names>H.S.</given-names></name>
<name><surname>Marinho</surname><given-names>M.M.</given-names></name>
<etal/>
</person-group><article-title>Molecular Docking and Antibacterial Activity of Campesterol Derivatives Against <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> Multiresistant Strains</article-title><source>Chem. Biodivers.</source><year>2024</year><volume>22</volume><elocation-id>e202401073</elocation-id><pub-id pub-id-type="doi">10.1002/cbdv.202401073</pub-id><pub-id pub-id-type="pmid">39258811</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00168"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>D.</given-names></name>
<name><surname>Davis</surname><given-names>A.M.</given-names></name>
<name><surname>Kleywegt</surname><given-names>G.J.</given-names></name>
<name><surname>Schmitt</surname><given-names>S.</given-names></name>
</person-group><article-title>An Alternative Method for the Evaluation of Docking Performance: RSR vs RMSD</article-title><source>J. Chem. Inf. Model.</source><year>2008</year><volume>48</volume><fpage>1411</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1021/ci800084x</pub-id><pub-id pub-id-type="pmid">18598022</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Table</title><fig position="float" id="pharmaceuticals-18-00168-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00168-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of <italic toggle="yes">allo</italic>-gibberic acid azides. (i) HCl, 1.2 M, 65 &#x000b0;C, 3 h, 70%. (ii) CH<sub>3</sub>I, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 1 h, 92%. (iii) LiAlH<sub>4</sub>, dry THF, 40 &#x000b0;C, 3 h, 81%. (iv) TsCl, DIPEA, DMAP (cat.), DCM, 40 &#x000b0;C, 24 h, 75%. (v) NaN<sub>3</sub>, DMF, 80 &#x000b0;C, 5 h, 78%. (vi) OsO<sub>4</sub>, NMO, acetone, RT, 24 h, 98%.</p></caption><graphic xlink:href="pharmaceuticals-18-00168-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-sch002"><object-id pub-id-type="pii">pharmaceuticals-18-00168-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Synthesis of 2,4-diaminopyrimidine-derived alkynes. (i) Propargylamine (2 eq.), TEA, MeCN, 25 &#x000b0;C, 24 h, <bold>8</bold> (65%), <bold>9</bold> (88%). (ii) (a) Trifluoromethylaniline (1.1 eq.), EtOH, MW, 150 &#x000b0;C, 200 W, 19 bar, 2 h, <bold>10</bold> (58%), <bold>11</bold> (52%); (b) 1-methyl-1<italic toggle="yes">H</italic>-pyrazol-4-amine (1.1 eq.), EtOH, MW, 150 &#x000b0;C, 200 W, 19 bar, 2 h, <bold>12</bold> (91%), <bold>13</bold> (50%); (c) methyl 4-aminobenzoate (1 eq.), EtOH, MW, 100 &#x000b0;C, 200 W, 17 bar, 2 h, <bold>14</bold> (28%), <bold>15</bold> (81%); (d) 4-morpholinoaniline (1 eq.), EtOH, MW, 100 &#x000b0;C, 200 W, 17 bar, 2 h, <bold>16</bold> (52%).</p></caption><graphic xlink:href="pharmaceuticals-18-00168-sch002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-sch003"><object-id pub-id-type="pii">pharmaceuticals-18-00168-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>Synthesis of <italic toggle="yes">allo</italic>-gibberic acid-based monoamino- and diaminopyrimidines. (i) Cu(OAc)<sub>2</sub>.H<sub>2</sub>O (5 mol%), Na ascorbate (10 mol%), alkyne (1.1 eq.), 45 &#x000b0;C, 48 h; solvent mixture: <italic toggle="yes">tert</italic>-BuOH/H<sub>2</sub>O (2:1) for <bold>17</bold> (42%), <bold>18</bold> (33%), <bold>19</bold> (30%), <bold>20</bold> (59%), <bold>21</bold> (45%), <bold>22</bold> (47%), <bold>24</bold> (36%), <bold>25</bold> (91%), <bold>26</bold> (51%), <bold>27</bold> (34%), <bold>28</bold> (52%), <bold>29</bold> (36%), <bold>30</bold> (69%), <bold>31</bold> (95%), and <bold>34</bold> (92%), THF: H<sub>2</sub>O (2:1) for <bold>23</bold> (79%), <bold>32</bold> (44%), and <bold>33</bold> (43%), and <italic toggle="yes">i</italic>-PrOH:H<sub>2</sub>O (2:1) for <bold>24</bold> (36%).</p></caption><graphic xlink:href="pharmaceuticals-18-00168-sch003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-f001"><label>Figure 1</label><caption><p>Relative configuration of azide <bold>5</bold> determined by NOESY experiment.</p></caption><graphic xlink:href="pharmaceuticals-18-00168-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) Three-dimensional presentation of the complex between a known inhibitor and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S). (<bold>B</bold>) Two-dimensional presentation of the interactions between a known inhibitor and <italic toggle="yes">P. aeruginosa</italic> DNA gyrase (PDB code: 6M1S).</p></caption><graphic xlink:href="pharmaceuticals-18-00168-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-f003"><label>Figure 3</label><caption><p>Three-dimensional presentation of (<bold>A</bold>) interactions between compound <bold>20</bold> and DNA gyrase of <italic toggle="yes">P. aeruginosa</italic> (PDB code: 6M1S) and (<bold>B</bold>) interactions between compound <bold>29</bold> and DNA gyrase of <italic toggle="yes">P. aeruginosa</italic> (PDB code: 6M1S).</p></caption><graphic xlink:href="pharmaceuticals-18-00168-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00168-f004"><label>Figure 4</label><caption><p>Three-dimensional presentation of the binding locations of the original ligand (yellow), compound <bold>20</bold> (green), compound <bold>29</bold> (cyan), and compound <bold>30</bold> (purple).</p></caption><graphic xlink:href="pharmaceuticals-18-00168-g004" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00168-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00168-t001_Table 1</object-id><label>Table 1</label><caption><p>Antimicrobial activities of the synthesized compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Inhibitory Effect (%) &#x000b1; RSD (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Gram-Positive</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Gram-Negative</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Yeast</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conc. (&#x003bc;g/mL)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">B. subtilis</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">C. krusei</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">C. albicans</italic>
</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ampicillin</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">99.7 &#x000b1; 2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">99.1 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">99.1 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">99.1 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.3 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>-</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Nystatine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.5 &#x000b1; 6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 2.0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 5.9</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">44.5 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">86.6 &#x000b1; 22.0</td><td align="center" valign="middle" rowspan="1" colspan="1">48.3 &#x000b1; 5.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.7 &#x000b1; 9.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.8 &#x000b1; 7.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.3 &#x000b1; 3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.0 &#x000b1; 6.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.5 &#x000b1; 2.5</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">3.2 &#x000b1; 3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">15.8 &#x000b1; 1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">4.6 &#x000b1; 7.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.6 &#x000b1; 5.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.5 &#x000b1; 4.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.9 &#x000b1; 3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.1 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9 &#x000b1; 2.2</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>17</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">58.7 &#x000b1; 3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.3 &#x000b1; 6.0</td><td align="center" valign="middle" rowspan="1" colspan="1">82.6 &#x000b1; 2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">22.8 &#x000b1; 5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">59.3 &#x000b1; 4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7 &#x000b1; 2.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.3 &#x000b1; 9.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.1 &#x000b1; 6.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.4 &#x000b1; 4.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.0 &#x000b1; 7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.8 &#x000b1; 4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>18</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">43.4 &#x000b1; 5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">31.0 &#x000b1; 5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">58.8 &#x000b1; 9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8 &#x000b1; 3.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.7 &#x000b1; 7.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.2 &#x000b1; 4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.4 &#x000b1; 3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.9 &#x000b1; 17.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.6 &#x000b1; 2.2</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>19</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">82.2 &#x000b1; 4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">50.6 &#x000b1; 3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">18.8 &#x000b1; 2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">19.8 &#x000b1; 3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">46.0 &#x000b1; 8.5</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.9 &#x000b1; 1.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3 &#x000b1; 1.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.5 &#x000b1; 2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>20</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">23.4 &#x000b1; 3.7</td><td align="center" valign="middle" rowspan="1" colspan="1">26.1 &#x000b1; 4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">17.2 &#x000b1; 4.9</td><td align="center" valign="middle" rowspan="1" colspan="1">81.6 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 &#x000b1; 3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9 &#x000b1; 2.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.8 &#x000b1; 4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.5 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 1.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.9 &#x000b1; 2.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.2 &#x000b1; 3.3</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>21</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">23.6 &#x000b1; 2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">27.2 &#x000b1; 5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">79.2 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">71.8 &#x000b1; 1.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.0 &#x000b1; 4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.0 &#x000b1; 4.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.6 &#x000b1; 8.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.3 &#x000b1; 1.1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>22</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5 &#x000b1; 1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">32.1 &#x000b1; 2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">58.6 &#x000b1; 3.2</td><td align="center" valign="middle" rowspan="1" colspan="1">47.1 &#x000b1; 0.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4 &#x000b1; 2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.3 &#x000b1; 8.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.2 &#x000b1; 10.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.1 &#x000b1; 0.6</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>23</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">48.1 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">57.4 &#x000b1; 5.7</td><td align="center" valign="middle" rowspan="1" colspan="1">49.8 &#x000b1; 1.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.1 &#x000b1; 6.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6 &#x000b1; 1.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.2 &#x000b1; 2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4 &#x000b1; 1.3</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>24</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">56.8 &#x000b1; 9.0</td><td align="center" valign="middle" rowspan="1" colspan="1">58.1 &#x000b1; 1.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.9 &#x000b1; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.6 &#x000b1; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.3 &#x000b1; 0.5</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>25</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1 &#x000b1; 2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">42.3 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">27.0 &#x000b1; 0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.1 &#x000b1; 5.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.5 &#x000b1; 0.3</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>26</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">17.5 &#x000b1; 6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">15.5 &#x000b1; 3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.5 &#x000b1; 13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2 &#x000b1; 1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.7 &#x000b1; 6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.3 &#x000b1; 12.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>27</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">22.7 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">30.2 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">61.3 &#x000b1; 10.8</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.5 &#x000b1; 7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.8 &#x000b1; 6.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.9 &#x000b1; 5.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 21.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.3 &#x000b1; 2.0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>28</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">96.5 &#x000b1; 5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">94.7 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">97.5 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">33.6 &#x000b1; 3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">26.7 &#x000b1; 8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6 &#x000b1; 1.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.9 &#x000b1; 2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.1 &#x000b1; 0.7</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>29</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">100.7 &#x000b1; 1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">50.1 &#x000b1; 5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">32.4 &#x000b1; 12.7</td><td align="center" valign="middle" rowspan="1" colspan="1">93.2 &#x000b1; 3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">84.0 &#x000b1; 5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">19.1 &#x000b1; 0.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7 &#x000b1; 5.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0 &#x000b1; 1.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.7 &#x000b1; 18.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>30</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">17.0 &#x000b1; 8.3</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">41.7 &#x000b1; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">48.1 &#x000b1; 0.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.7 &#x000b1; 6.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.5 &#x000b1; 2.3</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>31</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">61.2 &#x000b1; 3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">49.3 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">54.5 &#x000b1; 4.4</td><td align="center" valign="middle" rowspan="1" colspan="1">60.2 &#x000b1; 0.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.0 &#x000b1; 2.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.5 &#x000b1; 13.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.0 &#x000b1; 4.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.9 &#x000b1; 0.5</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>32</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">45.9 &#x000b1; 6.1</td><td align="center" valign="middle" rowspan="1" colspan="1">40.1 &#x000b1; 7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">15.9 &#x000b1; 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">53.8 &#x000b1; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">60.1 &#x000b1; 2.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.7 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.3 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4 &#x000b1; 4.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.2 &#x000b1; 10.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.6 &#x000b1; 0.8</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>33</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0 &#x000b1; 2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">60.7 &#x000b1; 18</td><td align="center" valign="middle" rowspan="1" colspan="1">38.4 &#x000b1; 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">57.0 &#x000b1; 6.9</td><td align="center" valign="middle" rowspan="1" colspan="1">67.3 &#x000b1; 0.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.1 &#x000b1; 4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.3 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.4 &#x000b1; 3.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.0 &#x000b1; 0.6</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>34</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">21.7 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">18.4 &#x000b1; 2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">50.7 &#x000b1; 3.2</td><td align="center" valign="middle" rowspan="1" colspan="1">29.6 &#x000b1; 0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.1 &#x000b1; 7.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.8 &#x000b1; 3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.1 &#x000b1; 9.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.6 &#x000b1; 0.3</td></tr></tbody></table></table-wrap></sec></back></article>